Perrigo (PRGO) 10-Q 2 Nov 15 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information Document - shares	3 Months Ended
	Sep. 26, 2015	Oct. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	PERRIGO CO PLC
Entity Central Index Key	1,585,364
Current Fiscal Year End Date	--06-25
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 26, 2015
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		146,402,066

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Sep. 26, 2015	Sep. 27, 2014
Net sales	$ 1,344.7	$ 951.5
Cost of sales	795.9	629.7
Gross profit	548.8	321.8
Operating expenses
Distribution	24.9	14.4
Research and development	41.6	36.6
Selling	167.9	50.4
Administration	123.6	81.5
Restructuring	2.2	1.7
Total operating expenses	360.2	184.6
Operating Income	188.6	137.2
Interest Income (Expense), Net	43.4	25.9
Other expense, net	13	2.7
Income before income taxes	132.2	108.6
Income tax expense	19.6	12.3
Net income	$ 112.6	$ 96.3
Earnings Per Share [Abstract]
Basic earnings per share	$ 0.77	$ 0.72
Diluted earnings per share	$ 0.77	$ 0.72
Weighted average shares outstanding
Basic	146.3	133.9
Diluted	146.9	134.4
Dividends declared per share	$ 0.125	$ 0.105

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Sep. 26, 2015	Sep. 27, 2014
Net income	$ 112.6	$ 96.3
Other Comprehensive Income (loss):
Foreign currency translation adjustments	(39.8)	(63.8)
Change in fair value of derivative financial instruments, net of tax	0.1	(2.1)
Change in fair value of investment securities, net of tax	2.5	0.6
Other comprehensive income (loss), net of tax	(37.2)	(65.3)
Comprehensive income	$ 75.4	$ 31

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) shares in Millions, $ in Millions	Sep. 26, 2015	Jun. 27, 2015
Assets
Cash and cash equivalents	$ 506.5	$ 785.6
Investment securities	16.5	12.7
Accounts receivable, net, current	1,232.2	1,282.1
Inventories	888	838.9
Current deferred income taxes	69	122.3
Prepaid expenses and other current assets	168.6	141.3
Total current assets	2,880.8	3,182.9
Property and equipment, net	924.1	932.4
Goodwill and other indefinite-lived intangible assets	7,355.2	7,235
Other intangible assets, net	8,290.2	8,105.6
Non-current deferred income taxes	27.8	39.6
Other non-current assets	225	225.1
Total non-current assets	16,822.3	16,537.7
Total Assets	19,703.1	19,720.6
Liabilities and Shareholders' Equity
Accounts payable	541.2	747.5
Short-term debt	86.9	6.4
Payroll and related taxes	112.2	133.9
Accrued customer programs	367.1	368.1
Accrued liabilities	308.8	246.4
Accrued income taxes	82.3	52.6
Current deferred income taxes	104.5	80.6
Current portion of long-term debt	58.2	58.2
Total current liabilities	1,661.2	1,693.7
Long-term debt, less current portion	5,229.9	5,246.9
Non-current deferred income taxes	1,705.1	1,745.1
Other non-current liabilities	374.9	372.1
Total non-current liabilities	7,309.9	7,364.1
Total liabilities	8,971.1	9,057.8
Commitments and contingencies disclosure [Abstract]
Preferred shares, $0.0001 par value, 10 million shares authorized	0	0
Common shares, €0.0001 par value, 10 billion shares authorized	8,632.8	8,621.9
Accumulated other comprehensive income	65.2	102.4
Retained earnings	2,034	1,938.3
Total controlling interest	10,732	10,662.6
Noncontrolling interest	0	0.2
Total shareholders' equity	10,732	10,662.8
Total liabilities and shareholders' equity	$ 19,703.1	$ 19,720.6
Supplemental Disclosures of Balance Sheet Information
Preferred shares, issued and outstanding	0	0
Ordinary shares, issued and outstanding	146.4	146.3
Perrigo Co PLC [Member]
Liabilities and Shareholders' Equity
Long-term debt, less current portion	$ 5,229.9	$ 5,246.8
Commitments and contingencies disclosure [Abstract]
Accumulated other comprehensive income	$ 65.2

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) shares in Millions, $ in Millions	Sep. 26, 2015€ / shares	Sep. 26, 2015USD ($)$ / sharesshares	Jun. 27, 2015€ / shares	Jun. 27, 2015USD ($)$ / sharesshares
Shareholders' Equity
Preferred shares, par value | $ / shares		$ 0.0001		$ 0.0001
Preferred shares, authorized		10		10
Ordinary shares, par value | € / shares	€ 0.001		€ 0.001
Ordinary shares, authorized		10,000		10,000
Preferred shares outstanding		0		0
Ordinary shares, outstanding		146.4		146.3
Allowance for Doubtful Accounts Receivable | $		$ 2.1		$ 2.4
Commitments and Contingencies | $		$ 0		$ 0

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Sep. 26, 2015	Sep. 27, 2014
Cash Flows From (For) Operating Activities
Net income	$ 112.6	$ 96.3
Adjustments to derive cash flows
Depreciation and amortization	175.4	126.6
Share-based Compensation	14.3	8.8
Non-cash restructuring charges	2.2	1.7
Deferred income taxes	(14.2)	(20.1)
Other non-cash adjustments	3.2	0.3
Subtotal	293.5	213.6
Increase (decrease) in cash due to
Accounts receivable	46.2	57.3
Inventories	(57)	(29.7)
Accounts payable	(194)	(32.5)
Payroll and related taxes	(22.8)	(34.9)
Accrued customer programs	(0.4)	18.1
Accrued liabilities	61.5	0.6
Accrued income taxes	15.2	14.6
Other	(6.2)	(12)
Subtotal	(157.5)	(18.5)
Net cash from (for) operating activities	136	195.1
Cash Flows (For) From Investing Activities
Acquisitions of business, net of cash acquired	405.1	0
Additions to property and equipment	(38.6)	(31.7)
Other investing	5	(1)
Net cash from (for) investing activities	(448.7)	(30.7)
Cash Flows (For) From Financing Activities
Repayment of long-term debt	(14.3)	(39.5)
Borrowings (repayments) of Short-term debt, net	79	(2.1)
Issuance of ordinary shares	2.2	2.6
Shares withheld for payment of employees' withholding tax liability	(9)	(7.5)
Cash dividends	(18.3)	(14.1)
Other Financing	4.1	(0.7)
Net cash from (for) financing activities	43.7	(61.3)
Effect of exchange rate changes on cash	(10.1)	(11.1)
Net increase (decrease) in cash and cash equivalents	(279.1)	92
Cash and cash equivalents, beginning of period	785.6	799.5
Cash and cash equivalents, end of period	506.5	891.5
Cash paid/received during the period for:
Interest paid	6.2	5.2
Interest received	0.3	0.2
Income taxes paid	19.8	10.9
Income taxes refunded	$ 1	$ 0.5

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 26, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Change in Accounting Principles [Text Block]	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES a. General Information The Company Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013. We became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo", the "Company", "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries. We are a leading over-the-counter ("OTC") consumer goods and specialty pharmaceutical company, offering patients and customers high-quality products at affordable prices. From our beginning in 1887 as a packager of generic home remedies, we have grown to become the world's largest manufacturer of OTC products and supplier of infant formulas for the store brand market. We are also a leading provider of generic extended topical prescription products, and we receive royalties from sales of the multiple sclerosis drug Tysabri ® . We provide “Quality Affordable Healthcare Products ® ” across a wide variety of product categories and geographies, primarily in North America, Europe and Australia, as well as in other markets, including Israel and China. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the consolidated financial statements and footnotes included in our Annual Report on Form 10-K for the fiscal year ended June 27, 2015 . In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation have been included. In fiscal year 2015, we announced that our fiscal year-end will begin on January 1 and end on December 31 of each year, starting on January 1, 2016. Fiscal year 2015, which ended on June 27, 2015, will be followed by a transition period from June 28, 2015 to December 31, 2015. We plan to disclose the results of the transition period on a Form 10-KT transition report. We will continue to close our books on the Saturday closest to end of the quarter, with the last quarter ending on December 31. This practice will only affect the quarterly reporting periods and not the annual reporting periods. Sales of OTC pharmaceutical products in the Consumer Healthcare ("CHC") segment are typically subject to seasonal demands for cough/cold/flu products from September through March and allergy products from April through September. Our Branded Consumer Healthcare ("BCH") sales are also impacted by seasonality and tend to peak in April through June due to increased demand for seasonal health and wellness products. In addition, our animal health products are subject to seasonal demand for flea and tick products that peaks during the warmer weather months, typically from March through June. Our Prescription Pharmaceuticals ( "Rx"), Specialty Sciences, and Other segments' sales are not generally impacted by seasonal conditions. Accordingly, operating results for the three months ended September 26, 2015 are not necessarily indicative of the results that may be expected for a full year. Principles of Consolidation The Condensed Consolidated Financial Statements include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. Accounts Receivable Factoring As a result of our acquisition of Omega Pharma Invest N.V. ("Omega"), we assumed multiple accounts receivable factoring arrangements with non-related third-party financial institutions (the “Factors”). Pursuant to the terms of the arrangements, we sell to the Factors certain of our accounts receivable balances on a non-recourse basis for credit approved accounts. An administrative fee ranging from 0.14% to 0.15% per invoice is charged on the gross amount of accounts receivables assigned to the Factors, plus interest is calculated at the applicable EUR LIBOR rate plus 70 basis points. The total amount factored and excluded from accounts receivable was $159.3 million at September 26, 2015 , a $12.3 million decrease since June 27, 2015 . b. Recent Accounting Standard Pronouncements Accounting Standard Update Description Date of Adoption Effect on the Financial Statements or Other Significant Matters Simplifying the Accounting for Measurement-Period Adjustments The updated guidance eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. Instead, acquirers must recognize measurement-period adjustments during the period in which they determine the amounts, including the effect on earnings of any amounts they would have recorded in previous periods if the accounting had been completed at the acquisition date. The guidance is effective for public business entities for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption is permitted. September 26, 2015 Provisional amounts that occur on or after the adoption date will be recognized in the period in which they are determined. The adoption of this accounting guidance did not materially impact the financial statements for the quarter ended September 26, 2015.

Business Acquisitions (Notes)

Business Acquisitions (Notes)	3 Months Ended
	Sep. 26, 2015
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	ACQUISITIONS All of the below acquisitions have been accounted for under the acquisition method of accounting based on our analysis of the acquired inputs and processes, and the related assets acquired and liabilities assumed were recorded at fair value as of the acquisition date. Fair value estimates are based on a complex series of judgments about future events and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets and liabilities assumed, as well as asset lives, can materially impact our results of operations. For those acquisitions for which the purchase price allocation is preliminary, we will continue to refine the allocation during the measurement period. As we obtain the information to finalize our purchase accounting assessments, it is reasonably possible that there will be changes in the valuation of assets acquired and liabilities assumed that may have a material impact on our results of operations and financial position. The effects of all of the acquisitions described below were included in the Condensed Consolidated Financial Statements prospectively from the date of each acquisition. Unless otherwise indicated, acquisition costs incurred were immaterial and were recorded in Administration expense. Current Period Acquisitions Naturwohl Pharma GmbH On September 15, 2015 , we completed our acquisition of 100% of Naturwohl Pharma GmbH ("Naturwohl"), a Munich, Germany-based nutritional business known for its leading German dietary supplement brand, Yokebe. The acquisition builds on our BCH segment's leading OTC product portfolio and European commercial infrastructure. The assets were purchased through an all-cash transaction valued at €133.5 million ( $150.4 million ). Operating results attributable to Naturwohl are included in the BCH segment. The intangible assets acquired included a trademark with a 15 -year useful life, customer relationships with a 15 -year useful life, non-compete agreements with a three -year useful life, and a licensing agreement with a three -year useful life. We utilized the relief from royalty method for valuing the trademark, the multi-period excess earnings method for valuing the customer relationships, the lost income method for valuing the non-compete agreements, and the with or without approach for the licensing agreement. The with or without approach estimates the fair value of an asset by comparing the value of the business, inclusive of the asset, to the hypothetical value of the same business excluding the asset. The goodwill acquired is not deductible for tax purposes. ScarAway ® On August 28, 2015 , we acquired ScarAway ® , a leading U.S. OTC scar management brand portfolio comprised of five products, from Enaltus, LLC, for $27.0 million in cash. This acquisition serves as our entry into the branded OTC business in the U.S. Operating results attributable to ScarAway ® are included in the CHC segment. The intangible assets acquired included a trademark with a 25 -year useful life, non-compete agreements with a four -year useful life and customer relationships with a 15 -year useful life. We utilized the relief from royalty method for valuing the trademark, the multi-period excess earnings method for valuing the customer relationships, and the lost income method for valuing the non-compete agreements. The goodwill acquired is deductible for tax purposes. GlaxoSmithKline Consumer Healthcare On August 28, 2015 , we completed the acquisition of a portfolio of well-established OTC brands from GlaxoSmithKline Consumer Healthcare (“GSK”). This acquisition further leverages our European market share and expands our product offerings. The assets were purchased through an all-cash transaction valued at €200.0 million ( $223.6 million ). Operating results attributable to GSK are included in the BCH segment. The intangible assets acquired included trademarks with 25 -year useful lives and customer relationships with a 15 -year useful life. We utilized the relief from royalty method for valuing the trademarks and the multi-period excess earnings method for valuing the customer relationships. The goodwill acquired is deductible for tax purposes. Other Product Acquisitions We also acquired two OTC product portfolios totaling €7.9 million ( $8.7 million ) during the three months ended September 26, 2015 , which are included in the BCH segment. Purchase Price Allocation of Current Period Acquisitions The Naturwohl, ScarAway ® , and GSK opening balance sheets are still preliminary and are based on valuation information, estimates, and assumptions available at September 26, 2015 . As we finalize the fair value estimates of assets acquired and liabilities assumed, additional purchase price adjustments may be recorded during the measurement period. Tax accounts as well as certain tangible and intangible assets have not yet been finalized. The below table indicates the purchase price allocation for our current period acquisitions (in millions): Naturwohl* ScarAway ® * GSK* Total purchase consideration $ 150.4 $ 27.0 $ 223.6 Assets acquired: Cash and cash equivalents $ 4.6 $ — $ — Accounts receivable 3.3 0.9 — Inventories 1.7 — — Prepaid expenses and other current assets — 0.1 — Goodwill 63.5 4.9 48.7 Intangible assets: Trademarks, trade names, and brands 51.8 11.6 132.4 Customer relationships and distribution networks 33.8 9.0 42.5 Non-competition agreements 0.3 0.5 — Distribution and license agreements 21.4 — — Other intangible assets 107.3 21.1 174.9 Total assets 180.4 27.0 223.6 Liabilities assumed: Accounts payable 2.8 — — Accrued liabilities 0.9 — — Current net deferred income tax liabilities 0.9 — — Non-current net deferred income tax liabilities 25.4 — — Total liabilities 30.0 — — Net assets acquired $ 150.4 $ 27.0 $ 223.6 * Opening balance sheets are preliminary. Prior Period Acquisitions Gelcaps Exportadora de Mexico, S.A. de C.V. On May 12, 2015 , we acquired 100% of Gelcaps Exportadora de Mexico, S.A. de C.V. ("Gelcaps"), the Mexican operations of Durham, North Carolina-based Patheon Inc., for $36.4 million in cash. The purchase price was adjusted during the three months ended September 26, 2015 to account for a working capital adjustment with the seller. The acquisition added softgel manufacturing technology to our supply chain capabilities and broadened our presence, product portfolio, and customer network in Mexico. Operating results attributable to Gelcaps are included in the CHC segment. The intangible assets acquired included a trademark with a 25 -year useful life and customer relationships with a 20 -year useful life. We utilized the relief from royalty method for valuing the trademark and the multi-period excess earnings method for valuing the customer relationships. Based on valuation estimates utilizing the comparative sales method, a step-up in the value of inventory of $0.6 million was recorded in the opening balance sheet, which was charged to cost of goods sold during the three months ended September 26, 2015 . In addition, property, plant and equipment were written up by $0.9 million to their estimated fair market value based on a valuation method that included both the cost and market approaches. This additional step-up in value is being depreciated over the estimated remaining useful lives of the assets. The goodwill recorded is not deductible for tax purposes. Omega Pharma Invest N.V. On March 30, 2015 , we completed our acquisition of Omega, a limited liability company incorporated under the laws of Belgium. Omega was a leading European OTC company, and is providing us several key benefits, including advancing our growth strategy outside the U.S. by providing access across a larger global platform with critical mass in key European countries, establishing commercial infrastructure in the high-barrier-to-entry European OTC marketplace, strengthening our product portfolio while enhancing scale and distribution, enhancing our financial profile, and expanding our international management capabilities. We purchased 95.77% of the issued and outstanding share capital of Omega ( 685,348,257 shares) from Alychlo N.V. (“Alychlo”) and Holdco I BE N.V. (“Holdco” and, together with Alychlo, the “Sellers”), limited liability companies incorporated under the laws of Belgium, under the terms of the Share Purchase Agreement dated November 6, 2014 (the "Share Purchase Agreement"). Omega holds the remaining 30,243,983 shares as treasury shares. The acquisition was a cash and stock transaction made up of the following consideration (in millions, except per share data): Perrigo ordinary shares issued 5.4 Perrigo share price at transaction close on March 30, 2015 $ 167.64 Total value of Perrigo ordinary shares issued $ 904.9 Cash consideration 2,078.3 Total consideration $ 2,983.2 The cash consideration shown in the above table was financed by a combination of debt and equity. We issued $1.6 billion of debt and 6.8 million ordinary shares, which raised $999.3 million net of issuance costs. The Sellers agreed to indemnify us for certain potential future losses. The Sellers’ indemnification and other obligations to us under the Share Purchase Agreement are secured up to €248.0 million ( $277.0 million ). Under the terms of the Share Purchase Agreement, Alychlo and its affiliates are subject to a three -year non-compete in Europe, and the Sellers are subject to a two -year non-solicit, in each case subject to certain exceptions. The Share Purchase Agreement contains other customary representations, warranties, and covenants of the parties thereto. The operating results attributable to Omega are included in the BCH segment. We incurred costs in connection with the Omega acquisition related to general transaction costs (legal, banking and other professional fees), financing fees, and debt extinguishment. The amounts recorded were not allocated to a reporting segment. The table below details the acquisition costs, as well as losses on hedging activities associated with the acquisition purchase price, and where they were recorded in the fiscal year ended June 27, 2015 (in millions): Line item June 27, Administration $ 29.7 Interest expense, net 23.7 Other expense, net 324.0 Loss on extinguishment of debt 9.6 Total acquisition-related costs $ 387.0 The $324.0 million loss recorded in Other expense, net, consisted of losses from hedging Omega's euro-denominated purchase price due to changes in the euro-to-U.S. dollar exchange rates. These losses were economically offset at closing in the final settlement of the euro-denominated purchase price. We acquired the following intangible assets: indefinite-lived brands, a definite-lived trade name with an eight -year useful life, definite-lived brands with a 19 -year useful life, a distribution network with a 21 -year useful life, and developed product technology with useful lives ranging from four to 13 years. We also recorded goodwill, which is not deductible for tax purposes and represents the value we assigned to the expected synergies described above. We utilized the multi-period excess earnings method for the indefinite-lived brands, the definite-lived brands, and distribution network. We utilized the relief from royalty method for the developed product technology and definite-lived trade name. Based on valuation estimates utilizing the comparative sales method, a step-up in the value of inventory of $15.1 million was recorded in the opening balance sheet and was charged to cost of goods sold during the three months ended June 27, 2015. In addition, property, plant and equipment were written up $41.5 million to their estimated fair market value based on a valuation method that included both the cost and market approaches during the three months ended June 27, 2015. This step-up in value is being depreciated over the estimated remaining useful lives of the assets. Additionally, the fair value of the debt assumed on the date of acquisition exceeded par value by $101.9 million , which was recorded as part of the carrying value of the underlying debt and will be amortized as a reduction of interest expense over the remaining terms of the respective debt instruments. For more information on the debt we assumed from Omega and our subsequent payments on the debt, see Note 8 . Lumara Health, Inc. On October 31, 2014 , we acquired a portfolio of women's healthcare products from Lumara Health, Inc., ("Lumara") a privately-held, Chesterfield, Missouri-based specialty pharmaceutical company, for cash consideration of $83.0 million . The acquisition of this portfolio further expanded our women's healthcare product offerings. Operating results attributable to the acquired Lumara products are included in the Rx segment. The intangible assets acquired consisted of three product formulations with useful lives ranging from eight to 12 years. The assets were valued utilizing the multi-period excess earnings method. Purchase Price Allocation of Prior Period Acquisitions The Lumara opening balance sheet is final. The Omega and Gelcaps opening balance sheets are still preliminary and are based on valuation information, estimates, and assumptions available at September 26, 2015 . Since the initial valuation, revisions to the Omega allocation have included: a $98.0 million increase in indefinite-lived brands and an $18.4 million increase in definite-lived intangible assets (trade names, brands, and distribution networks) due to refinements in underlying valuation assumptions; a $7.4 million reduction in inventory due to additional analysis related to the fair value of inventory and obsolescence reserves; a $9.6 million increase in property, plant, and equipment due to the completion of additional tangible asset valuations; and an increase in the net deferred tax liabilities of $31.6 million due to the valuation update. These revisions resulted in an $87.0 million reduction in goodwill. The purchase price allocation is still open for verification of the intangible assets valuation, related deferred taxes, and the resulting effects on the value of goodwill. The Gelcaps purchase price allocation is open for verification of the intangible assets valuation, tax accounts, and any resulting effects on the value of goodwill. The below table indicates the purchase price allocation for our prior year acquisitions (in millions): Gelcaps* Omega* Lumara Total purchase consideration $ 36.4 $ 2,983.2 $ 83.0 Assets acquired: Cash and cash equivalents $ 4.6 $ 14.7 $ — Accounts receivable 8.5 264.7 2.9 Inventories 7.2 207.1 1.5 Current net deferred tax assets 0.6 7.6 — Prepaid expenses and other current assets 2.3 39.2 0.4 Property and equipment 6.0 130.8 0.1 Goodwill 4.6 1,426.1 — Intangible assets: Trademarks, trade names and brands 4.4 2,492.6 — Customer relationships and distribution networks 6.6 1,393.9 — Formulations — — 82.0 Developed product technology — 32.6 — Other intangible assets 11.0 3,919.1 82.0 Other non-current assets 0.4 2.4 — Total assets 45.2 6,011.7 86.9 Liabilities assumed: Accounts payable 3.4 243.1 — Short-term debt — 24.6 — Accrued liabilities 1.6 44.5 3.9 Payroll and related taxes — 51.3 — Accrued customer programs — 39.8 — Long-term debt — 1,471.0 — Non-current net deferred income tax liabilities 3.7 1,071.7 — Other non-current liabilities 0.1 82.5 — Total liabilities 8.8 3,028.5 3.9 Net assets acquired $ 36.4 $ 2,983.2 $ 83.0 * Opening balance sheets are preliminary.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	3 Months Ended
	Sep. 26, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets [Text Block]	GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions): Reporting Segments: Balance at June 27, 2015 Business Acquisitions Purchase Accounting Adjustments Currency Translation Adjustment Balance at September 26, 2015 CHC $ 1,897.5 $ 4.9 $ (0.2 ) $ (3.8 ) $ 1,898.4 BCH 1,551.9 112.2 (87.0 ) 0.4 1,577.5 Rx 1,233.6 — — (8.1 ) 1,225.5 Specialty Sciences 200.7 — — — 200.7 Other 88.2 — — (3.2 ) 85.0 Total goodwill $ 4,971.9 $ 117.1 $ (87.2 ) $ (14.7 ) $ 4,987.1 Intangible Assets Other intangible assets and related accumulated amortization consisted of the following (in millions): September 26, 2015 June 27, 2015 Gross Accumulated Amortization Gross Accumulated Amortization Definite-lived intangibles : Distribution and license agreements $ 6,064.2 $ 582.6 $ 6,029.9 $ 502.3 Developed product technology/formulation and product rights 1,015.4 402.5 1,025.3 383.1 Customer relationships and distribution networks 1,888.2 181.5 1,749.9 146.2 Trademarks, trade names, and brands 502.8 16.7 340.8 11.5 Non-compete agreements 15.2 12.3 14.7 11.9 Total definite-lived intangibles $ 9,485.8 $ 1,195.6 $ 9,160.6 $ 1,055.0 Indefinite-lived intangibles : Trademarks, trade names, and brands $ 2,362.5 $ — $ 2,257.3 $ — In-process research and development 5.6 — 5.8 — Total indefinite-lived intangibles 2,368.1 — 2,263.1 — Total other intangible assets $ 11,853.9 $ 1,195.6 $ 11,423.7 $ 1,055.0 Certain intangible assets are denominated in currencies other than the U.S. dollar; therefore, their gross and net carrying values are subject to foreign currency movements. We recorded amortization expense of $147.6 million and $106.5 million for the three months ended September 26, 2015 and September 27, 2014 , respectively. The increase in amortization expense was due primarily to the incremental amortization expense incurred on the definite-lived intangible assets acquired from Omega.

Inventories (Notes)

Inventories (Notes)	3 Months Ended
	Sep. 26, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	INVENTORIES Major components of inventory at September 26, 2015 and June 27, 2015 , were as follows (in millions): September 26, June 27, Finished goods $ 504.7 $ 468.9 Work in process 163.2 158.2 Raw materials 220.1 211.8 Total inventories $ 888.0 $ 838.9

Fair value measurements (Note)

Fair value measurements (Note)	3 Months Ended
	Sep. 26, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	FAIR VALUE MEASUREMENTS Fair value is the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy is used in selecting inputs, with the highest priority given to Level 1, as these are the most transparent or reliable. Level 1: Quoted prices for identical instruments in active markets. Level 2: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level 3: Valuations derived from valuation techniques in which one or more significant inputs are not observable. The following tables summarize the valuation of our financial instruments carried at fair value by the above pricing categories at September 26, 2015 and June 27, 2015 (in millions): September 26, 2015 Level 1 Level 2 Level 3 Total Assets: Investment securities $ 16.5 $ — $ — $ 16.5 Foreign currency forward contracts — 4.8 — 4.8 Funds associated with Israeli post-employment benefits — 16.5 — 16.5 Total assets $ 16.5 $ 21.3 $ — $ 37.8 Liabilities: Foreign currency forward contracts — 5.9 — 5.9 Total liabilities $ — $ 5.9 $ — $ 5.9 June 27, 2015 Level 1 Level 2 Level 3 Total Assets: Investment securities $ 12.7 $ — $ — $ 12.7 Foreign currency forward contracts — 12.4 — 12.4 Funds associated with Israeli post-employment benefits — 17.3 — 17.3 Total assets $ 12.7 $ 29.7 $ — $ 42.4 Liabilities: Foreign currency forward contracts — 4.6 — 4.6 Total liabilities $ — $ 4.6 $ — $ 4.6 There were no transfers between Levels 1, 2, and 3 during the three months ended September 26, 2015 . Our policy regarding the recording of transfers between levels is to record any such transfers at the end of the reporting period. See Note 6 for information on our investment securities. See Note 7 for a discussion of derivatives. Israeli post-employment benefits represent amounts we have deposited in funds managed by financial institutions designated by management to cover post-employment benefits for its Israeli employees as required by Israeli law. The funds are recorded in Other non-current assets and values are determined using prices for recently traded financial instruments with similar underlying terms, as well as directly or indirectly observable inputs, such as interest rates and yield curves, that are observable at commonly quoted intervals. As of September 26, 2015 and June 27, 2015 , our fixed rate long-term debt consisted of public bonds, retail bonds, and private placement notes. The fair value of the public bonds was determined by quoted market prices (Level 1). As of September 26, 2015 , the public bonds had a carrying value of $3.9 billion and a fair value of $3.8 billion . As of June 27, 2015 , the public bonds had a carrying value and a fair value of $3.9 billion . The fair value of the retail bonds and private placement notes was determined by discounting the future cash flows of the financial instruments to their present value, using interest rates offered for borrowings of a similar nature and remaining maturities (Level 2). As of September 26, 2015 and June 27, 2015 , the retail bonds and private placement notes had a carrying value of $822.7 million and $820.9 million , respectively, and a fair value of $890.9 million and $902.4 million , respectively. The carrying amounts of our other financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, short-term debt and variable rate long-term debt, approximate their fair value.

Investments (Notes)

Investments (Notes)	3 Months Ended
	Sep. 26, 2015
Investments [Abstract]
Cost and Equity Method Investments Disclosure [Text Block]	INVESTMENTS Available for Sale Securities Our available for sale securities are reported in Investment securities . Unrealized investment gains (losses) on available for sale securities were as follows (in millions): September 26, 2015 June 27, 2015 Equity securities, at cost less impairments $ 17.1 $ 17.1 Gross unrealized gains 10.6 5.7 Gross unrealized losses (11.2 ) (10.1 ) Estimated fair value of equity securities $ 16.5 $ 12.7 The factors affecting the assessment of impairments include both general financial market conditions and factors specific to a particular company. The equity securities in a gross unrealized loss position at September 26, 2015 were in that position for less than 12 months. We have evaluated the near-term prospects of the equity securities in relation to the severity and duration of the unrealized impairments, and based on that evaluation, we have the ability and intent to hold the investments until a recovery of fair value. Cost Method Investments Our cost method investments totaled $6.9 million and $6.8 million at September 26, 2015 and June 27, 2015 , respectively, and are included in Other non-current assets . Equity Method Investments Our equity method investments totaled $48.5 million and $48.9 million at September 26, 2015 and June 27, 2015 , respectively, and are included in Other non-current assets . We recorded net losses of $4.1 million and $3.1 million during the three months ended September 26, 2015 and September 27, 2014 , respectively, for our proportionate share of the equity method investment earnings or losses. The losses were recorded in Other expense, net.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities (Note)	3 Months Ended
	Sep. 26, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES We enter into certain derivative financial instruments, when available on a cost-effective basis, to mitigate our risk associated with changes in interest rates and foreign currency exchange rates as follows: Interest rate risk management - We are exposed to the impact of interest rate changes through our cash investments and borrowings. We utilize a variety of strategies to manage the impact of changes in interest rates including using a mix of debt maturities along with both fixed-rate and variable-rate debt. In addition, we may enter into treasury-lock agreements and interest rate swap agreements on certain investing and borrowing transactions to manage our exposure to interest rate changes and our overall cost of borrowing. Foreign currency exchange risk management - We conduct business in several major currencies other than the U.S. dollar and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency sales and expenses. All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be offset largely by gains and losses on the original underlying asset or liability. We do not use derivative financial instruments for speculative purposes. All of our designated derivatives were classified as cash flow hedges as of September 26, 2015 and June 27, 2015 . Designated derivatives meet hedge accounting criteria, which means the fair value of the hedge is recorded in shareholders’ equity as a component of Other Comprehensive Income ("OCI"), net of tax. The deferred gains and losses are recognized in income in the period in which the hedged item affects earnings. Any ineffective portion of the change in fair value of the derivative is immediately recognized in earnings, recorded in Other expense, net. All of our designated derivatives are assessed for hedge effectiveness quarterly. We also have economic non-designated derivatives that do not meet hedge accounting criteria. These derivative instruments are adjusted to current market value at the end of each period through earnings. Gains or losses on these instruments are offset substantially by the remeasurement adjustment on the hedged item. Interest Rate Swaps and Treasury Locks Interest rate swap agreements are contracts to exchange floating rate for fixed rate payments (or vice versa) over the life of the agreement without the exchange of the underlying notional amounts. The notional amounts of the interest rate swap agreements are used to measure interest to be paid or received and do not represent the amount of exposure to credit loss. The differential paid or received on the interest rate swap agreements is recognized as an adjustment to interest expense. All of our interest rate swaps qualify for hedge accounting treatment. Foreign Currency Derivatives We enter into foreign currency forward contracts, both designated and non-designated, in order to manage the impact of foreign exchange fluctuations on expected future purchases and related payables denominated in a foreign currency, as well as to hedge the impact of foreign exchange fluctuations on expected future sales and related receivables denominated in a foreign currency. Both types of forward contracts have a maximum maturity date of 15 months. The total notional amount for these contracts was $562.3 million and $452.3 million as of September 26, 2015 and June 27, 2015 , respectively. Effects of Derivatives on the Financial Statements The below tables indicate the effects of all derivative instruments on the Condensed Consolidated Financial Statements at September 26, 2015 and June 27, 2015 . All amounts exclude income tax effects and are presented in millions. The balance sheet location and gross fair value of our outstanding derivative instruments were as follows: Asset Derivatives Balance Sheet Location Fair Value September 26, 2015 June 27, 2015 Designated derivatives: Foreign currency forward contracts Other current assets $ 2.3 $ 3.3 Total designated derivatives $ 2.3 $ 3.3 Non-designated derivatives: Foreign currency forward contracts Other current assets $ 2.5 $ 9.1 Total non-designated derivatives $ 2.5 $ 9.1 Liability Derivatives Balance Sheet Location Fair Value September 26, 2015 June 27, 2015 Designated derivatives: Foreign currency forward contracts Accrued liabilities $ 2.5 $ 2.0 Total designated derivatives $ 2.5 $ 2.0 Non-designated derivatives: Foreign currency forward contracts Accrued liabilities $ 3.4 $ 2.6 Total non-designated derivatives $ 3.4 $ 2.6 The gains (losses) recognized in OCI for the effective portion of our designated cash flow hedges were as follows: Amount of Gain/(Loss) Recorded in OCI Three Months Ended Designated Cash Flow Hedges September 26, 2015 September 27, 2014 Interest rate swap agreements — 2.7 Foreign currency forward contracts (0.5 ) (5.2 ) $ (0.5 ) $ (2.5 ) The gains (losses) reclassified from Accumulated Other Comprehensive Income ("AOCI") into earnings for the effective portion of our designated cash flow hedges were as follows: Designated Cash Flow Hedges Income Statement Location Amount of Gain/(Loss) Reclassified from AOCI to Income Three Months Ended September 26, 2015 September 27, 2014 Interest rate swap agreements Interest expense, net (0.4 ) (0.9 ) Foreign currency forward contracts Net sales (0.1 ) 0.6 Cost of sales 0.2 0.4 Other expense, net (0.1 ) (0.8 ) $ (0.4 ) $ (0.7 ) The net of tax amount expected to be reclassified out of AOCI into earnings during the next 12 months is a $1.8 million loss. The effects of our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows: Non-Designated Derivatives Income Statement Location Amount of Gain/(Loss) Recognized in Income Three Months Ended September 26, 2015 September 27, 2014 Foreign currency forward contracts Other expense, net $ (8.9 ) $ (1.8 ) Interest expense, net 0.1 (1.5 ) Total $ (8.8 ) $ (3.3 )
Derivatives, Policy [Policy Text Block]	We enter into certain derivative financial instruments, when available on a cost-effective basis, to mitigate our risk associated with changes in interest rates and foreign currency exchange rates as follows: Interest rate risk management - We are exposed to the impact of interest rate changes through our cash investments and borrowings. We utilize a variety of strategies to manage the impact of changes in interest rates including using a mix of debt maturities along with both fixed-rate and variable-rate debt. In addition, we may enter into treasury-lock agreements and interest rate swap agreements on certain investing and borrowing transactions to manage our exposure to interest rate changes and our overall cost of borrowing. Foreign currency exchange risk management - We conduct business in several major currencies other than the U.S. dollar and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency sales and expenses. All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be offset largely by gains and losses on the original underlying asset or liability. We do not use derivative financial instruments for speculative purposes. All of our designated derivatives were classified as cash flow hedges as of September 26, 2015 and June 27, 2015 . Designated derivatives meet hedge accounting criteria, which means the fair value of the hedge is recorded in shareholders’ equity as a component of Other Comprehensive Income ("OCI"), net of tax. The deferred gains and losses are recognized in income in the period in which the hedged item affects earnings. Any ineffective portion of the change in fair value of the derivative is immediately recognized in earnings, recorded in Other expense, net. All of our designated derivatives are assessed for hedge effectiveness quarterly. We also have economic non-designated derivatives that do not meet hedge accounting criteria. These derivative instruments are adjusted to current market value at the end of each period through earnings. Gains or losses on these instruments are offset substantially by the remeasurement adjustment on the hedged item.

Indebtedness (note)

Indebtedness (note)	3 Months Ended
	Sep. 26, 2015
Aggregate Indebtedness [Abstract]
Indebtedness [Text Block]	INDEBTEDNESS Total borrowings outstanding at September 26, 2015 and June 27, 2015 are summarized as follows (in millions): September 26, June 27, Short-term debt $ 86.9 $ 6.4 Term loans * 2014 Term loan due December 5, 2019 517.7 530.5 Public bonds Coupon Due 1.300% November 8, 2016 (3) 500.0 500.0 * 4.500% May 23, 2017 (2) 201.5 201.0 * 5.125% December 12, 2017 (2) 335.8 335.0 2.300% November 8, 2018 (3) 600.0 600.0 * 5.000% May 23, 2019 (2) 134.3 134.1 3.500% December 15, 2021 (1) 500.0 500.0 * 5.105% July 19, 2023 (2) 151.1 150.8 4.000% November 15, 2023 (3) 800.0 800.0 3.900% December 15, 2024 (1) 700.0 700.0 5.300% November 15, 2043 (3) 400.0 400.0 4.900% December 15, 2044 (1) 400.0 400.0 Total public bonds 4,722.7 4,720.9 Other financing 6.3 6.6 Unamortized premium (discount), net 80.4 87.5 Deferred financing fees (39.0 ) (40.5 ) Total borrowings outstanding 5,375.0 5,311.4 Less short-term debt and current portion of long-term debt (145.1 ) (64.6 ) Total long-term debt less current portion $ 5,229.9 $ 5,246.8 (1) Public bonds issued on December 2, 2014, discussed below collectively as the "2014 Bonds." (2) Debt assumed from Omega. (3) Discussed below collectively as the "2013 Bonds." * Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate. We were in compliance with all covenants under our various debt agreements as of September 26, 2015 and June 27, 2015 . Our term loan and revolving credit facility each have an event of default for changes of control that would be triggered upon a 35% change of control. Also, if there is a change of control under our $3.9 billion of public senior notes (the 2014 Bonds and 2013 Bonds), and they are downgraded below investment grade by both Moody's Investor Services, Inc. and Standard & Poor's Rating Service, we would be obligated to offer to repurchase all of the 2014 Bonds and 2013 Bonds at 101% of par. Omega Financing Debt Issuance On December 2, 2014 , Perrigo Finance plc, our 100% owned finance subsidiary ("Perrigo Finance"), issued $500.0 million in aggregate principal amount of 3.50% senior notes due 2021 (the "2021 Notes”), $700.0 million in aggregate principal amount of 3.90% senior notes due 2024 (the “2024 Notes”), and $400.0 million in aggregate principal amount of 4.90% senior notes due 2044 (the “2044 Notes” and, together with the 2021 Notes and the 2024 Notes, the “2014 Bonds”). Interest on the 2014 Bonds is payable semiannually in arrears in June and December of each year, beginning in June 2015. The 2014 Bonds are governed by a base indenture and a first supplemental indenture (collectively, the "2014 Indenture"). The 2014 Bonds are fully and unconditionally guaranteed on a senior unsecured basis by Perrigo Company plc, and no other subsidiary of Perrigo Company plc guarantees the 2014 Bonds. There are no restrictions under the 2014 Bonds on our ability to obtain funds from our subsidiaries. Perrigo Finance received net proceeds of approximately $1.6 billion from issuance of the 2014 Bonds after fees and market discount. Perrigo Finance may redeem the 2014 Bonds in whole or in part at any time for cash at the make-whole redemption prices described in the 2014 Indenture. On December 5, 2014 , Perrigo Finance entered into a term loan agreement consisting of a €500.0 million ( $614.3 million ) tranche, with the ability to draw an additional €300.0 million ( $368.6 million ) tranche, maturing December 5, 2019, and a $600.0 million revolving credit agreement, which stepped up to $1.0 billion upon the closing of the Omega acquisition (the "2014 Revolver") (together, the "2014 Credit Agreements"). On the same date, Perrigo Company plc entered into a $300.0 million term loan tranche maturing December 18, 2015, which we repaid on June 14, 2015. There were no borrowings outstanding under the 2014 Revolver as of September 26, 2015 . Subsequent to September 26, 2015 , we allowed the undrawn €300.0 million term loan tranche to expire. Assumed Debt and Repayment In connection with the Omega acquisition, we assumed $20.0 million in aggregate principal amount of 6.19% senior notes due 2016 ("2016 Notes"), €135.0 million ( $147.0 million ) in aggregate principal amount of 5.1045% senior notes due 2023 ("2023 Notes"), €300.0 million ( $326.7 million ) in aggregate principal amount of 5.125% retail bonds due 2017 , €180.0 million ( $196.0 million ) in aggregate principal amount of 4.500% retail bonds due 2017 , €120.0 million ( $130.7 million ) in aggregate principal amount of 5.000% retail bonds due 2019 (collectively, the "Retail Bonds"), a revolving credit facility with €500.0 million ( $544.5 million ) outstanding, and certain overdraft facilities totaling €51.4 million ( $56.0 million ). The fair value of the 2023 Notes and Retail Bonds exceeded par value by €93.6 million ( $101.9 million ) on the date of the acquisition. As a result, a fair value adjustment was recorded as part of the carrying value of the underlying debt and will be amortized as a reduction of interest expense over the remaining terms of the respective debt instruments. The adjustment does not affect cash interest payments. On April 8, 2015 , we repaid the €500.0 million ( $539.1 million ) outstanding under the assumed Omega revolving credit facility and terminated the facility. On May 29, 2015, we repaid the $20.0 million outstanding on the 2016 Notes. Omega regularly utilizes overdraft facilities to meet its short-term liquidity needs and its balances fluctuate on a day-to-day basis. While the assumed overdraft facilities balance noted above was repaid as of June 27, 2015 , additional borrowings were made as of September 26, 2015 and make up the majority of the short-term debt balance in the above table. Elan Financing Debt Issuance On November 8, 2013, Perrigo Company issued $500.0 million aggregate principal amount of its 1.300% senior notes due 2016 (the "2016 Notes"), $600.0 million aggregate principal amount of its 2.300% senior notes due 2018 (the "2018 Notes"), $800.0 million aggregate principal amount of its 4.000% senior notes due 2023 (the "2023 Notes") and $400.0 million aggregate principal amount of its 5.300% senior notes due 2043 (the "2043 Notes" and, together with the 2016 Notes, the 2018 Notes and the 2023 Notes, the "2013 Bonds") in a private placement with registration rights. Interest on the 2013 Bonds is payable semiannually in arrears in May and November of each year, beginning in May 2014. The 2013 Bonds are governed by a base indenture and a first supplemental indenture (collectively, the "2013 Indenture"). The 2013 Bonds are the Company's unsecured and unsubordinated obligations, ranking equally in right of payment to all of Perrigo Company's existing and future unsecured and unsubordinated indebtedness. Perrigo Company received net proceeds of $2.3 billion from the issuance of the 2013 Bonds after fees and market discount. The 2013 Bonds are not entitled to mandatory redemption or sinking fund payments. We may redeem the 2013 Bonds in whole or in part at any time for cash at the make-whole redemption prices described in the 2013 Indenture. The 2013 Bonds were guaranteed on an unsubordinated, unsecured basis by the same entities that guaranteed our 2013 credit agreements until November 21, 2014, at which time the 2013 Indenture was amended to remove all guarantors. On September 2, 2014, we offered to exchange our private placement senior notes with public bonds. The offer was open until October 1, 2014, at which time substantially all of the private placement notes had been exchanged for bonds registered with the Securities and Exchange Commission. As a result of the changes in the guarantor structure noted above, we are no longer required to present guarantor financial statements.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Sep. 26, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY Earnings per Share A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions): Three Months Ended September 26, September 27, Numerator: Net income $ 112.6 $ 96.3 Denominator: Weighted average shares outstanding for basic EPS 146.3 133.9 Dilutive effect of share-based awards 0.6 0.5 Weighted average shares outstanding for diluted EPS 146.9 134.4 Anti-dilutive share-based awards excluded from computation of diluted EPS 0.1 0.1 Shareholders' Equity On and prior to December 18, 2013, our common stock consisted of common stock of Perrigo Company, a Michigan Corporation, and since December 19, 2013, our common stock has consisted of ordinary shares of Perrigo Company plc, incorporated under the laws of Ireland. Prior to June 6, 2013, our common stock traded on the NASDAQ Global Select Market under the symbol PRGO. Since June 6, 2013, our ordinary shares have traded on the New York Stock Exchange under the symbol PRGO. In association with the acquisition of Agis Industries (1983) Ltd., our ordinary shares have been trading on the Tel Aviv Stock Exchange since March 16, 2005. We issued 154 thousand and 186 thousand shares related to the exercise and vesting of share-based compensation during the three months ended September 26, 2015 and September 27, 2014 , respectively. As of September 26, 2015 , we did not have an ordinary share repurchase program. O n October 22, 2015 , we announced a $2.0 billion share repurchase plan over three years, including $500.0 million expected to be repurchased during the fourth quarter of calendar year 2015.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	3 Months Ended
	Sep. 26, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Comprehensive Income (Loss) Note [Text Block]	ACCUMULATED OTHER COMPREHENSIVE INCOME Changes in our AOCI balances, net of tax, for the three months ended September 26, 2015 were as follows (in millions): Foreign currency translation adjustments Fair value of derivative financial instruments, net of tax Fair value of investment securities, net of tax Post-retirement and pension liability adjustments, net of tax Total AOCI Balance at June 27, 2015 $ 130.9 $ (16.3 ) $ (3.0 ) $ (9.2 ) $ 102.4 OCI before reclassifications (39.8 ) (0.3 ) 2.5 — (37.6 ) Amounts reclassified from AOCI — 0.4 — — 0.4 Other comprehensive income (39.8 ) 0.1 2.5 — (37.2 ) Balance at September 26, 2015 $ 91.1 $ (16.2 ) $ (0.5 ) $ (9.2 ) $ 65.2

Income Taxes

Income Taxes	3 Months Ended
	Sep. 26, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	INCOME TAXES The effective tax rate was 14.8% and 11.4% for the three months ended September 26, 2015 and September 27, 2014 , respectively. Our tax rate is subject to adjustment over the balance of the prior fiscal year ended due to, among other things: income tax rate changes by governments; the jurisdictions in which our profits are determined to be earned and taxed; changes in the valuation of our deferred tax assets and liabilities; adjustments to estimated taxes upon finalization of various tax returns; adjustments to our interpretation of transfer pricing standards; changes in available tax credits, grants and other incentives; changes in stock-based compensation expense; changes in tax laws or the interpretation of such tax laws (for example, proposals for fundamental U.S. international tax reform); changes in U.S. GAAP; expiration of or the inability to renew tax rulings or tax holiday incentives; and the repatriation of earnings with respect to which we have not previously provided for taxes. The total liability for uncertain tax positions was $399.0 million and $384.3 million as of September 26, 2015 and June 27, 2015 , respectively, before considering the federal tax benefit of certain state and local items. We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. The total amount accrued for interest and penalties in the liability for uncertain tax positions was $69.0 million and $65.7 million as of September 26, 2015 and June 27, 2015 , respectively. We file income tax returns in numerous jurisdictions and are therefore subject to audits by tax authorities. Our primary income tax jurisdictions are Ireland, the U.S., Israel, Belgium, France, and the United Kingdom (U.K.). Although we believe that the tax estimates are reasonable and that we prepare our tax filings in accordance with all applicable tax laws, the final determination with respect to any tax audit, and any related litigation, could be materially different from estimates or from historical income tax provisions and accruals. The results of an audit or litigation could have a material effect on our operating results or cash flows in the periods for which that determination is made. In addition, future period earnings may be adversely impacted by litigation costs, settlements, penalties, or interest assessments. We are under audit by the Israel Tax Authority and the Internal Revenue Service ("IRS") for the fiscal year ended June 25, 2011 and June 30, 2012. The IRS audit of the fiscal year ended June 27, 2009 and June 26, 2010 had previously concluded with the issuance of a statutory notice of deficiency on August 27, 2014. While we had previously agreed on certain adjustments and made associated payments of $8.0 million , inclusive of interest, in November 2014, the statutory notice of deficiency asserted various additional positions, including transfer pricing, relative to the same fiscal year ended June 27, 2009 and June 26, 2010 audit. The statutory notice asserted an incremental tax obligation of approximately $68.9 million , inclusive of interest and penalties. We disagree with the IRS’s positions asserted in the notice of deficiency. In January 2015, we paid this amount, a prerequisite to being able to contest the IRS’s positions in U.S. Federal court, and in June 2015, we filed a request for a refund. As the IRS has denied our request for a refund, we intend to contest the IRS’s asserted positions in U.S. Federal court. The payment was recorded as a deferred charge on the balance sheet given our anticipated action to recover this amount. An unfavorable resolution of this matter could have a material impact on our consolidated financial statements in future periods. There are numerous other income tax jurisdictions for which tax returns are not yet settled, none of which are individually significant. At this time, we cannot predict the outcome of any audit or related litigation.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 26, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies [Text Block]	COMMITMENTS AND CONTINGENCIES In addition to the discussions below, we have pending certain other legal actions and claims incurred in the normal course of business. We record accruals for such contingencies when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of September 26, 2015 , we have determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. We have accrued for these matters and will continue to monitor each related legal issue and adjust accruals for new information and further development. Other than what is disclosed below, we consider the litigation matters to be immaterial individually and in the aggregate. Texas Medicaid In June 2013, we received notices from the Office of the Attorney General for the State of Texas, of civil investigative demands to two of our affiliates, Perrigo Pharmaceuticals Company and Paddock Laboratories, LLC, for information under the Texas Medicaid Fraud Prevention Act relating to the submission of prices to Texas Medicaid in claims for reimbursement for drugs. We have cooperated with requests for information and are in the process of evaluating this and other information. While we do not know the full extent of our potential liability at this time and intend to vigorously defend against any claims, we could be subject to material penalties and damages. We initially established a contingency loss accrual of $15.0 million to cover potential settlement or other outcomes. Due to changes in circumstances, during the three months ended March 28, 2015, we accrued an additional $9.0 million . In addition, we recorded a receivable of $7.0 million representing the amount we expect to collect from the previous owners of Paddock Laboratories, LLC. We cannot predict whether we will obtain a settlement on terms we deem acceptable, or whether a settlement or potential liability for these claims will be materially higher than the amount recorded. Eltroxin During October and November 2011, nine applications to certify a class action lawsuit were filed in various courts in Israel related to Eltroxin, a prescription thyroid medication manufactured by a third party and distributed in Israel by Perrigo Israel Agencies Ltd. The respondents include Perrigo Israel Pharmaceuticals Ltd. and/or Perrigo Israel Agencies Ltd., the manufacturers of the product, and various healthcare providers who provide healthcare services as part of the compulsory healthcare system in Israel. One of the applications was dismissed and the remaining eight applications were consolidated into one application. The applications arose from the 2011 launch of a reformulated version of Eltroxin in Israel. The consolidated application generally alleges that the respondents (a) failed to timely inform patients, pharmacists and physicians about the change in the formulation; and (b) failed to inform physicians about the need to monitor patients taking the new formulation in order to confirm patients were receiving the appropriate dose of the drug. As a result, claimants allege they incurred the following damages: (a) purchases of product that otherwise would not have been made by patients had they been aware of the reformulation; (b) adverse events to some patients resulting from an imbalance of thyroid functions that could have been avoided; and (c) harm resulting from the patients' lack of informed consent prior to the use of the reformulation. Several hearings on whether or not to certify the consolidated application took place in December 2013 and January 2014. On May 17, 2015, the District Court certified the motion against Perrigo Israel Agencies Ltd. and dismissed it against the remaining respondents, including Perrigo Israel Pharmaceuticals Ltd. On June 16, 2015, Perrigo submitted a motion for permission to appeal the decision to certify to the Israeli Supreme Court together with a motion to stay the proceedings of the class action until the motion for permission to appeal is adjudicated. Other than requiring Perrigo to file its statement of defense to the underlying proceedings, the underlying proceedings have been stayed pending a decision on the motion to appeal. At this stage, we cannot reasonably predict the outcome or the liability, if any, associated with these claims. Tysabri ® Product Liability Lawsuits Perrigo Company plc and collaborator Biogen Idec are co-defendants in product liability lawsuits arising out of the occurrence of Progressive Multifocal Leukoencephalopathy, a serious brain infection, and serious adverse events, including deaths, which occurred in patients taking Tysabri ® . Perrigo Company plc and Biogen Idec will each be responsible for 50% of losses and expenses arising out of any Tysabri ® product liability claims. While these lawsuits will be vigorously defended, management cannot predict how these cases will be resolved. Adverse results in one or more of these lawsuits could result in substantial judgments against us.

Segment Information

Segment Information	3 Months Ended
	Sep. 26, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	SEGMENT INFORMATION Our reporting segments are as follows: • CHC is focused primarily on the global sale of OTC store brand products including cough, cold, and allergy products, gastrointestinal products, analgesics, nicotine-replacement therapy ("NRT"), Vitamins, Minerals and Supplements ("VMS"), animal health products, infant formula and foods, and diagnostic products. • BCH develops, manufactures, markets and distributes some of Europe's most well-known OTC brands in the natural health and VMS, cough, cold and allergy, NRT, personal care and derma-therapeutics, lifestyle, and anti-parasite categories. • Rx develops, manufactures and markets a portfolio of generic and specialty pharmaceutical prescription drugs primarily for the U.S. and U.K. markets. • Specialty Sciences is comprised primarily of royalties received from assets focused on the management of multiple sclerosis (Tysabri ® ). We also have an "Other" segment comprised of our active pharmaceutical ingredient ("API") business, which develops, manufactures, and markets active API used worldwide by both generic and branded pharmaceutical companies. The below tables show select financial measures by reporting segment (in millions): Three Months Ended Balance at September 26, 2015 September 26, 2015 Net Sales Operating Income (Loss) Amortization of Intangibles Total Assets CHC $ 675.2 $ 117.3 $ 19.4 $ 4,211.2 BCH 302.2 4.4 36.3 6,728.0 Rx 260.3 91.0 18.6 2,597.6 Specialty Sciences 84.5 9.0 72.8 5,920.8 Other 22.5 6.2 0.5 245.5 Unallocated expenses — (39.3 ) — — Total $ 1,344.7 $ 188.6 $ 147.6 $ 19,703.1 Three Months Ended Balance at June 27, 2015 September 27, 2014 Net Sales Operating Income (Loss) Amortization of Intangibles Total Assets CHC $ 640.3 $ 74.8 $ 16.2 $ 4,381.6 BCH — — — 6,441.1 Rx 194.5 64.7 17.0 2,667.9 Specialty Sciences 91.9 14.9 72.8 5,979.0 Other 24.8 7.1 0.5 251.0 Unallocated expenses — (24.3 ) — — Total $ 951.5 $ 137.2 $ 106.5 $ 19,720.6

Subsequent events (Notes)

Subsequent events (Notes)	3 Months Ended
	Sep. 26, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	SUBSEQUENT EVENTS On October 22, 2015, we announced that we intend to undertake certain initiatives designed to increase operational efficiency and improve our return on invested capital by globalizing our supply chain through global shared service arrangements, streamlining our organizational structure, and disposing of certain assets.

Summary of Significant Accoun21

Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)	3 Months Ended
	Sep. 26, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the consolidated financial statements and footnotes included in our Annual Report on Form 10-K for the fiscal year ended June 27, 2015 . In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation have been included. In fiscal year 2015, we announced that our fiscal year-end will begin on January 1 and end on December 31 of each year, starting on January 1, 2016. Fiscal year 2015, which ended on June 27, 2015, will be followed by a transition period from June 28, 2015 to December 31, 2015. We plan to disclose the results of the transition period on a Form 10-KT transition report. We will continue to close our books on the Saturday closest to end of the quarter, with the last quarter ending on December 31. This practice will only affect the quarterly reporting periods and not the annual reporting periods. Sales of OTC pharmaceutical products in the Consumer Healthcare ("CHC") segment are typically subject to seasonal demands for cough/cold/flu products from September through March and allergy products from April through September. Our Branded Consumer Healthcare ("BCH") sales are also impacted by seasonality and tend to peak in April through June due to increased demand for seasonal health and wellness products. In addition, our animal health products are subject to seasonal demand for flea and tick products that peaks during the warmer weather months, typically from March through June. Our Prescription Pharmaceuticals ( "Rx"), Specialty Sciences, and Other segments' sales are not generally impacted by seasonal conditions. Accordingly, operating results for the three months ended September 26, 2015 are not necessarily indicative of the results that may be expected for a full year.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The Condensed Consolidated Financial Statements include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
Transfers and Servicing of Financial Assets, Transfers of Financial Assets, Sales, Policy [Policy Text Block]	Accounts Receivable Factoring As a result of our acquisition of Omega Pharma Invest N.V. ("Omega"), we assumed multiple accounts receivable factoring arrangements with non-related third-party financial institutions (the “Factors”). Pursuant to the terms of the arrangements, we sell to the Factors certain of our accounts receivable balances on a non-recourse basis for credit approved accounts. An administrative fee ranging from 0.14% to 0.15% per invoice is charged on the gross amount of accounts receivables assigned to the Factors, plus interest is calculated at the applicable EUR LIBOR rate plus 70 basis points. The total amount factored and excluded from accounts receivable was $159.3 million at September 26, 2015 , a $12.3 million decrease since June 27, 2015 .
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	Recent Accounting Standard Pronouncements Accounting Standard Update Description Date of Adoption Effect on the Financial Statements or Other Significant Matters Simplifying the Accounting for Measurement-Period Adjustments The updated guidance eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. Instead, acquirers must recognize measurement-period adjustments during the period in which they determine the amounts, including the effect on earnings of any amounts they would have recorded in previous periods if the accounting had been completed at the acquisition date. The guidance is effective for public business entities for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption is permitted. September 26, 2015 Provisional amounts that occur on or after the adoption date will be recognized in the period in which they are determined. The adoption of this accounting guidance did not materially impact the financial statements for the quarter ended September 26, 2015.

Business Acquisitions (Tables)

Business Acquisitions (Tables)	3 Months Ended
	Sep. 26, 2015
Business Acquisition [Line Items]
Fair value of consideration transferred in business acquisition [Table Text Block]	The acquisition was a cash and stock transaction made up of the following consideration (in millions, except per share data): Perrigo ordinary shares issued 5.4 Perrigo share price at transaction close on March 30, 2015 $ 167.64 Total value of Perrigo ordinary shares issued $ 904.9 Cash consideration 2,078.3 Total consideration $ 2,983.2
Schedule of acquisition-related costs [Table Text Block]	The table below details the acquisition costs, as well as losses on hedging activities associated with the acquisition purchase price, and where they were recorded in the fiscal year ended June 27, 2015 (in millions): Line item June 27, Administration $ 29.7 Interest expense, net 23.7 Other expense, net 324.0 Loss on extinguishment of debt 9.6 Total acquisition-related costs $ 387.0
Naturwohl, GSK, Scaraway [Member]
Business Acquisition [Line Items]
Business Combination, Separately Recognized Transactions [Table Text Block]	The below table indicates the purchase price allocation for our current period acquisitions (in millions): Naturwohl* ScarAway ® * GSK* Total purchase consideration $ 150.4 $ 27.0 $ 223.6 Assets acquired: Cash and cash equivalents $ 4.6 $ — $ — Accounts receivable 3.3 0.9 — Inventories 1.7 — — Prepaid expenses and other current assets — 0.1 — Goodwill 63.5 4.9 48.7 Intangible assets: Trademarks, trade names, and brands 51.8 11.6 132.4 Customer relationships and distribution networks 33.8 9.0 42.5 Non-competition agreements 0.3 0.5 — Distribution and license agreements 21.4 — — Other intangible assets 107.3 21.1 174.9 Total assets 180.4 27.0 223.6 Liabilities assumed: Accounts payable 2.8 — — Accrued liabilities 0.9 — — Current net deferred income tax liabilities 0.9 — — Non-current net deferred income tax liabilities 25.4 — — Total liabilities 30.0 — — Net assets acquired $ 150.4 $ 27.0 $ 223.6 * Opening balance sheets are preliminary.
Omega, Gelcaps, Lumara [Member]
Business Acquisition [Line Items]
Business Combination, Separately Recognized Transactions [Table Text Block]	ACQUISITIONS All of the below acquisitions have been accounted for under the acquisition method of accounting based on our analysis of the acquired inputs and processes, and the related assets acquired and liabilities assumed were recorded at fair value as of the acquisition date. Fair value estimates are based on a complex series of judgments about future events and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets and liabilities assumed, as well as asset lives, can materially impact our results of operations. For those acquisitions for which the purchase price allocation is preliminary, we will continue to refine the allocation during the measurement period. As we obtain the information to finalize our purchase accounting assessments, it is reasonably possible that there will be changes in the valuation of assets acquired and liabilities assumed that may have a material impact on our results of operations and financial position. The effects of all of the acquisitions described below were included in the Condensed Consolidated Financial Statements prospectively from the date of each acquisition. Unless otherwise indicated, acquisition costs incurred were immaterial and were recorded in Administration expense. Current Period Acquisitions Naturwohl Pharma GmbH On September 15, 2015 , we completed our acquisition of 100% of Naturwohl Pharma GmbH ("Naturwohl"), a Munich, Germany-based nutritional business known for its leading German dietary supplement brand, Yokebe. The acquisition builds on our BCH segment's leading OTC product portfolio and European commercial infrastructure. The assets were purchased through an all-cash transaction valued at €133.5 million ( $150.4 million ). Operating results attributable to Naturwohl are included in the BCH segment. The intangible assets acquired included a trademark with a 15 -year useful life, customer relationships with a 15 -year useful life, non-compete agreements with a three -year useful life, and a licensing agreement with a three -year useful life. We utilized the relief from royalty method for valuing the trademark, the multi-period excess earnings method for valuing the customer relationships, the lost income method for valuing the non-compete agreements, and the with or without approach for the licensing agreement. The with or without approach estimates the fair value of an asset by comparing the value of the business, inclusive of the asset, to the hypothetical value of the same business excluding the asset. The goodwill acquired is not deductible for tax purposes. ScarAway ® On August 28, 2015 , we acquired ScarAway ® , a leading U.S. OTC scar management brand portfolio comprised of five products, from Enaltus, LLC, for $27.0 million in cash. This acquisition serves as our entry into the branded OTC business in the U.S. Operating results attributable to ScarAway ® are included in the CHC segment. The intangible assets acquired included a trademark with a 25 -year useful life, non-compete agreements with a four -year useful life and customer relationships with a 15 -year useful life. We utilized the relief from royalty method for valuing the trademark, the multi-period excess earnings method for valuing the customer relationships, and the lost income method for valuing the non-compete agreements. The goodwill acquired is deductible for tax purposes. GlaxoSmithKline Consumer Healthcare On August 28, 2015 , we completed the acquisition of a portfolio of well-established OTC brands from GlaxoSmithKline Consumer Healthcare (“GSK”). This acquisition further leverages our European market share and expands our product offerings. The assets were purchased through an all-cash transaction valued at €200.0 million ( $223.6 million ). Operating results attributable to GSK are included in the BCH segment. The intangible assets acquired included trademarks with 25 -year useful lives and customer relationships with a 15 -year useful life. We utilized the relief from royalty method for valuing the trademarks and the multi-period excess earnings method for valuing the customer relationships. The goodwill acquired is deductible for tax purposes. Other Product Acquisitions We also acquired two OTC product portfolios totaling €7.9 million ( $8.7 million ) during the three months ended September 26, 2015 , which are included in the BCH segment. Purchase Price Allocation of Current Period Acquisitions The Naturwohl, ScarAway ® , and GSK opening balance sheets are still preliminary and are based on valuation information, estimates, and assumptions available at September 26, 2015 . As we finalize the fair value estimates of assets acquired and liabilities assumed, additional purchase price adjustments may be recorded during the measurement period. Tax accounts as well as certain tangible and intangible assets have not yet been finalized. The below table indicates the purchase price allocation for our current period acquisitions (in millions): Naturwohl* ScarAway ® * GSK* Total purchase consideration $ 150.4 $ 27.0 $ 223.6 Assets acquired: Cash and cash equivalents $ 4.6 $ — $ — Accounts receivable 3.3 0.9 — Inventories 1.7 — — Prepaid expenses and other current assets — 0.1 — Goodwill 63.5 4.9 48.7 Intangible assets: Trademarks, trade names, and brands 51.8 11.6 132.4 Customer relationships and distribution networks 33.8 9.0 42.5 Non-competition agreements 0.3 0.5 — Distribution and license agreements 21.4 — — Other intangible assets 107.3 21.1 174.9 Total assets 180.4 27.0 223.6 Liabilities assumed: Accounts payable 2.8 — — Accrued liabilities 0.9 — — Current net deferred income tax liabilities 0.9 — — Non-current net deferred income tax liabilities 25.4 — — Total liabilities 30.0 — — Net assets acquired $ 150.4 $ 27.0 $ 223.6 * Opening balance sheets are preliminary. Prior Period Acquisitions Gelcaps Exportadora de Mexico, S.A. de C.V. On May 12, 2015 , we acquired 100% of Gelcaps Exportadora de Mexico, S.A. de C.V. ("Gelcaps"), the Mexican operations of Durham, North Carolina-based Patheon Inc., for $36.4 million in cash. The purchase price was adjusted during the three months ended September 26, 2015 to account for a working capital adjustment with the seller. The acquisition added softgel manufacturing technology to our supply chain capabilities and broadened our presence, product portfolio, and customer network in Mexico. Operating results attributable to Gelcaps are included in the CHC segment. The intangible assets acquired included a trademark with a 25 -year useful life and customer relationships with a 20 -year useful life. We utilized the relief from royalty method for valuing the trademark and the multi-period excess earnings method for valuing the customer relationships. Based on valuation estimates utilizing the comparative sales method, a step-up in the value of inventory of $0.6 million was recorded in the opening balance sheet, which was charged to cost of goods sold during the three months ended September 26, 2015 . In addition, property, plant and equipment were written up by $0.9 million to their estimated fair market value based on a valuation method that included both the cost and market approaches. This additional step-up in value is being depreciated over the estimated remaining useful lives of the assets. The goodwill recorded is not deductible for tax purposes. Omega Pharma Invest N.V. On March 30, 2015 , we completed our acquisition of Omega, a limited liability company incorporated under the laws of Belgium. Omega was a leading European OTC company, and is providing us several key benefits, including advancing our growth strategy outside the U.S. by providing access across a larger global platform with critical mass in key European countries, establishing commercial infrastructure in the high-barrier-to-entry European OTC marketplace, strengthening our product portfolio while enhancing scale and distribution, enhancing our financial profile, and expanding our international management capabilities. We purchased 95.77% of the issued and outstanding share capital of Omega ( 685,348,257 shares) from Alychlo N.V. (“Alychlo”) and Holdco I BE N.V. (“Holdco” and, together with Alychlo, the “Sellers”), limited liability companies incorporated under the laws of Belgium, under the terms of the Share Purchase Agreement dated November 6, 2014 (the "Share Purchase Agreement"). Omega holds the remaining 30,243,983 shares as treasury shares. The acquisition was a cash and stock transaction made up of the following consideration (in millions, except per share data): Perrigo ordinary shares issued 5.4 Perrigo share price at transaction close on March 30, 2015 $ 167.64 Total value of Perrigo ordinary shares issued $ 904.9 Cash consideration 2,078.3 Total consideration $ 2,983.2 The cash consideration shown in the above table was financed by a combination of debt and equity. We issued $1.6 billion of debt and 6.8 million ordinary shares, which raised $999.3 million net of issuance costs. The Sellers agreed to indemnify us for certain potential future losses. The Sellers’ indemnification and other obligations to us under the Share Purchase Agreement are secured up to €248.0 million ( $277.0 million ). Under the terms of the Share Purchase Agreement, Alychlo and its affiliates are subject to a three -year non-compete in Europe, and the Sellers are subject to a two -year non-solicit, in each case subject to certain exceptions. The Share Purchase Agreement contains other customary representations, warranties, and covenants of the parties thereto. The operating results attributable to Omega are included in the BCH segment. We incurred costs in connection with the Omega acquisition related to general transaction costs (legal, banking and other professional fees), financing fees, and debt extinguishment. The amounts recorded were not allocated to a reporting segment. The table below details the acquisition costs, as well as losses on hedging activities associated with the acquisition purchase price, and where they were recorded in the fiscal year ended June 27, 2015 (in millions): Line item June 27, Administration $ 29.7 Interest expense, net 23.7 Other expense, net 324.0 Loss on extinguishment of debt 9.6 Total acquisition-related costs $ 387.0 The $324.0 million loss recorded in Other expense, net, consisted of losses from hedging Omega's euro-denominated purchase price due to changes in the euro-to-U.S. dollar exchange rates. These losses were economically offset at closing in the final settlement of the euro-denominated purchase price. We acquired the following intangible assets: indefinite-lived brands, a definite-lived trade name with an eight -year useful life, definite-lived brands with a 19 -year useful life, a distribution network with a 21 -year useful life, and developed product technology with useful lives ranging from four to 13 years. We also recorded goodwill, which is not deductible for tax purposes and represents the value we assigned to the expected synergies described above. We utilized the multi-period excess earnings method for the indefinite-lived brands, the definite-lived brands, and distribution network. We utilized the relief from royalty method for the developed product technology and definite-lived trade name. Based on valuation estimates utilizing the comparative sales method, a step-up in the value of inventory of $15.1 million was recorded in the opening balance sheet and was charged to cost of goods sold during the three months ended June 27, 2015. In addition, property, plant and equipment were written up $41.5 million to their estimated fair market value based on a valuation method that included both the cost and market approaches during the three months ended June 27, 2015. This step-up in value is being depreciated over the estimated remaining useful lives of the assets. Additionally, the fair value of the debt assumed on the date of acquisition exceeded par value by $101.9 million , which was recorded as part of the carrying value of the underlying debt and will be amortized as a reduction of interest expense over the remaining terms of the respective debt instruments. For more information on the debt we assumed from Omega and our subsequent payments on the debt, see Note 8 . Lumara Health, Inc. On October 31, 2014 , we acquired a portfolio of women's healthcare products from Lumara Health, Inc., ("Lumara") a privately-held, Chesterfield, Missouri-based specialty pharmaceutical company, for cash consideration of $83.0 million . The acquisition of this portfolio further expanded our women's healthcare product offerings. Operating results attributable to the acquired Lumara products are included in the Rx segment. The intangible assets acquired consisted of three product formulations with useful lives ranging from eight to 12 years. The assets were valued utilizing the multi-period excess earnings method. Purchase Price Allocation of Prior Period Acquisitions The Lumara opening balance sheet is final. The Omega and Gelcaps opening balance sheets are still preliminary and are based on valuation information, estimates, and assumptions available at September 26, 2015 . Since the initial valuation, revisions to the Omega allocation have included: a $98.0 million increase in indefinite-lived brands and an $18.4 million increase in definite-lived intangible assets (trade names, brands, and distribution networks) due to refinements in underlying valuation assumptions; a $7.4 million reduction in inventory due to additional analysis related to the fair value of inventory and obsolescence reserves; a $9.6 million increase in property, plant, and equipment due to the completion of additional tangible asset valuations; and an increase in the net deferred tax liabilities of $31.6 million due to the valuation update. These revisions resulted in an $87.0 million reduction in goodwill. The purchase price allocation is still open for verification of the intangible assets valuation, related deferred taxes, and the resulting effects on the value of goodwill. The Gelcaps purchase price allocation is open for verification of the intangible assets valuation, tax accounts, and any resulting effects on the value of goodwill. The below table indicates the purchase price allocation for our prior year acquisitions (in millions): Gelcaps* Omega* Lumara Total purchase consideration $ 36.4 $ 2,983.2 $ 83.0 Assets acquired: Cash and cash equivalents $ 4.6 $ 14.7 $ — Accounts receivable 8.5 264.7 2.9 Inventories 7.2 207.1 1.5 Current net deferred tax assets 0.6 7.6 — Prepaid expenses and other current assets 2.3 39.2 0.4 Property and equipment 6.0 130.8 0.1 Goodwill 4.6 1,426.1 — Intangible assets: Trademarks, trade names and brands 4.4 2,492.6 — Customer relationships and distribution networks 6.6 1,393.9 — Formulations — — 82.0 Developed product technology — 32.6 — Other intangible assets 11.0 3,919.1 82.0 Other non-current assets 0.4 2.4 — Total assets 45.2 6,011.7 86.9 Liabilities assumed: Accounts payable 3.4 243.1 — Short-term debt — 24.6 — Accrued liabilities 1.6 44.5 3.9 Payroll and related taxes — 51.3 — Accrued customer programs — 39.8 — Long-term debt — 1,471.0 — Non-current net deferred income tax liabilities 3.7 1,071.7 — Other non-current liabilities 0.1 82.5 — Total liabilities 8.8 3,028.5 3.9 Net assets acquired $ 36.4 $ 2,983.2 $ 83.0 * Opening balance sheets are preliminary.

Goodwill and Other Intangible23

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Sep. 26, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill [Table Text Block]	Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions): Reporting Segments: Balance at June 27, 2015 Business Acquisitions Purchase Accounting Adjustments Currency Translation Adjustment Balance at September 26, 2015 CHC $ 1,897.5 $ 4.9 $ (0.2 ) $ (3.8 ) $ 1,898.4 BCH 1,551.9 112.2 (87.0 ) 0.4 1,577.5 Rx 1,233.6 — — (8.1 ) 1,225.5 Specialty Sciences 200.7 — — — 200.7 Other 88.2 — — (3.2 ) 85.0 Total goodwill $ 4,971.9 $ 117.1 $ (87.2 ) $ (14.7 ) $ 4,987.1
Schedule of Finite and Indefinite-Lived Intangible Assets [Table Text Block]	Other intangible assets and related accumulated amortization consisted of the following (in millions): September 26, 2015 June 27, 2015 Gross Accumulated Amortization Gross Accumulated Amortization Definite-lived intangibles : Distribution and license agreements $ 6,064.2 $ 582.6 $ 6,029.9 $ 502.3 Developed product technology/formulation and product rights 1,015.4 402.5 1,025.3 383.1 Customer relationships and distribution networks 1,888.2 181.5 1,749.9 146.2 Trademarks, trade names, and brands 502.8 16.7 340.8 11.5 Non-compete agreements 15.2 12.3 14.7 11.9 Total definite-lived intangibles $ 9,485.8 $ 1,195.6 $ 9,160.6 $ 1,055.0 Indefinite-lived intangibles : Trademarks, trade names, and brands $ 2,362.5 $ — $ 2,257.3 $ — In-process research and development 5.6 — 5.8 — Total indefinite-lived intangibles 2,368.1 — 2,263.1 — Total other intangible assets $ 11,853.9 $ 1,195.6 $ 11,423.7 $ 1,055.0

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Sep. 26, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Major components of inventory at September 26, 2015 and June 27, 2015 , were as follows (in millions): September 26, June 27, Finished goods $ 504.7 $ 468.9 Work in process 163.2 158.2 Raw materials 220.1 211.8 Total inventories $ 888.0 $ 838.9

Fair value measurements (Tables

Fair value measurements (Tables)	3 Months Ended
	Sep. 26, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following tables summarize the valuation of our financial instruments carried at fair value by the above pricing categories at September 26, 2015 and June 27, 2015 (in millions): September 26, 2015 Level 1 Level 2 Level 3 Total Assets: Investment securities $ 16.5 $ — $ — $ 16.5 Foreign currency forward contracts — 4.8 — 4.8 Funds associated with Israeli post-employment benefits — 16.5 — 16.5 Total assets $ 16.5 $ 21.3 $ — $ 37.8 Liabilities: Foreign currency forward contracts — 5.9 — 5.9 Total liabilities $ — $ 5.9 $ — $ 5.9 June 27, 2015 Level 1 Level 2 Level 3 Total Assets: Investment securities $ 12.7 $ — $ — $ 12.7 Foreign currency forward contracts — 12.4 — 12.4 Funds associated with Israeli post-employment benefits — 17.3 — 17.3 Total assets $ 12.7 $ 29.7 $ — $ 42.4 Liabilities: Foreign currency forward contracts — 4.6 — 4.6 Total liabilities $ — $ 4.6 $ — $ 4.6

Investments (Tables)

Investments (Tables)	3 Months Ended
	Sep. 26, 2015
Investments [Abstract]
Unrealized Gain (Loss) on Investments [Table Text Block]	Unrealized investment gains (losses) on available for sale securities were as follows (in millions): September 26, 2015 June 27, 2015 Equity securities, at cost less impairments $ 17.1 $ 17.1 Gross unrealized gains 10.6 5.7 Gross unrealized losses (11.2 ) (10.1 ) Estimated fair value of equity securities $ 16.5 $ 12.7

Derivative Instruments and He27

Derivative Instruments and Hedging Activities (Tables)	3 Months Ended
	Sep. 26, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	The balance sheet location and gross fair value of our outstanding derivative instruments were as follows: Asset Derivatives Balance Sheet Location Fair Value September 26, 2015 June 27, 2015 Designated derivatives: Foreign currency forward contracts Other current assets $ 2.3 $ 3.3 Total designated derivatives $ 2.3 $ 3.3 Non-designated derivatives: Foreign currency forward contracts Other current assets $ 2.5 $ 9.1 Total non-designated derivatives $ 2.5 $ 9.1 Liability Derivatives Balance Sheet Location Fair Value September 26, 2015 June 27, 2015 Designated derivatives: Foreign currency forward contracts Accrued liabilities $ 2.5 $ 2.0 Total designated derivatives $ 2.5 $ 2.0 Non-designated derivatives: Foreign currency forward contracts Accrued liabilities $ 3.4 $ 2.6 Total non-designated derivatives $ 3.4 $ 2.6
Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]	The gains (losses) recognized in OCI for the effective portion of our designated cash flow hedges were as follows: Amount of Gain/(Loss) Recorded in OCI Three Months Ended Designated Cash Flow Hedges September 26, 2015 September 27, 2014 Interest rate swap agreements — 2.7 Foreign currency forward contracts (0.5 ) (5.2 ) $ (0.5 ) $ (2.5 )
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	The gains (losses) reclassified from Accumulated Other Comprehensive Income ("AOCI") into earnings for the effective portion of our designated cash flow hedges were as follows: Designated Cash Flow Hedges Income Statement Location Amount of Gain/(Loss) Reclassified from AOCI to Income Three Months Ended September 26, 2015 September 27, 2014 Interest rate swap agreements Interest expense, net (0.4 ) (0.9 ) Foreign currency forward contracts Net sales (0.1 ) 0.6 Cost of sales 0.2 0.4 Other expense, net (0.1 ) (0.8 ) $ (0.4 ) $ (0.7 )
Schedule of non-designated derivatives	The effects of our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows: Non-Designated Derivatives Income Statement Location Amount of Gain/(Loss) Recognized in Income Three Months Ended September 26, 2015 September 27, 2014 Foreign currency forward contracts Other expense, net $ (8.9 ) $ (1.8 ) Interest expense, net 0.1 (1.5 ) Total $ (8.8 ) $ (3.3 )

Indebtedness (Tables)

Indebtedness (Tables)	3 Months Ended
	Sep. 26, 2015
Indebtness [Abstract]
Schedule of Debt [Table Text Block]	Total borrowings outstanding at September 26, 2015 and June 27, 2015 are summarized as follows (in millions): September 26, June 27, Short-term debt $ 86.9 $ 6.4 Term loans * 2014 Term loan due December 5, 2019 517.7 530.5 Public bonds Coupon Due 1.300% November 8, 2016 (3) 500.0 500.0 * 4.500% May 23, 2017 (2) 201.5 201.0 * 5.125% December 12, 2017 (2) 335.8 335.0 2.300% November 8, 2018 (3) 600.0 600.0 * 5.000% May 23, 2019 (2) 134.3 134.1 3.500% December 15, 2021 (1) 500.0 500.0 * 5.105% July 19, 2023 (2) 151.1 150.8 4.000% November 15, 2023 (3) 800.0 800.0 3.900% December 15, 2024 (1) 700.0 700.0 5.300% November 15, 2043 (3) 400.0 400.0 4.900% December 15, 2044 (1) 400.0 400.0 Total public bonds 4,722.7 4,720.9 Other financing 6.3 6.6 Unamortized premium (discount), net 80.4 87.5 Deferred financing fees (39.0 ) (40.5 ) Total borrowings outstanding 5,375.0 5,311.4 Less short-term debt and current portion of long-term debt (145.1 ) (64.6 ) Total long-term debt less current portion $ 5,229.9 $ 5,246.8 (1) Public bonds issued on December 2, 2014, discussed below collectively as the "2014 Bonds." (2) Debt assumed from Omega. (3) Discussed below collectively as the "2013 Bonds." * Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Sep. 26, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions): Three Months Ended September 26, September 27, Numerator: Net income $ 112.6 $ 96.3 Denominator: Weighted average shares outstanding for basic EPS 146.3 133.9 Dilutive effect of share-based awards 0.6 0.5 Weighted average shares outstanding for diluted EPS 146.9 134.4 Anti-dilutive share-based awards excluded from computation of diluted EPS 0.1 0.1

Accumulated Other Comprehensi30

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Sep. 26, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in our AOCI balances, net of tax, for the three months ended September 26, 2015 were as follows (in millions): Foreign currency translation adjustments Fair value of derivative financial instruments, net of tax Fair value of investment securities, net of tax Post-retirement and pension liability adjustments, net of tax Total AOCI Balance at June 27, 2015 $ 130.9 $ (16.3 ) $ (3.0 ) $ (9.2 ) $ 102.4 OCI before reclassifications (39.8 ) (0.3 ) 2.5 — (37.6 ) Amounts reclassified from AOCI — 0.4 — — 0.4 Other comprehensive income (39.8 ) 0.1 2.5 — (37.2 ) Balance at September 26, 2015 $ 91.1 $ (16.2 ) $ (0.5 ) $ (9.2 ) $ 65.2

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Sep. 26, 2015
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	The below tables show select financial measures by reporting segment (in millions): Three Months Ended Balance at September 26, 2015 September 26, 2015 Net Sales Operating Income (Loss) Amortization of Intangibles Total Assets CHC $ 675.2 $ 117.3 $ 19.4 $ 4,211.2 BCH 302.2 4.4 36.3 6,728.0 Rx 260.3 91.0 18.6 2,597.6 Specialty Sciences 84.5 9.0 72.8 5,920.8 Other 22.5 6.2 0.5 245.5 Unallocated expenses — (39.3 ) — — Total $ 1,344.7 $ 188.6 $ 147.6 $ 19,703.1 Three Months Ended Balance at June 27, 2015 September 27, 2014 Net Sales Operating Income (Loss) Amortization of Intangibles Total Assets CHC $ 640.3 $ 74.8 $ 16.2 $ 4,381.6 BCH — — — 6,441.1 Rx 194.5 64.7 17.0 2,667.9 Specialty Sciences 91.9 14.9 72.8 5,979.0 Other 24.8 7.1 0.5 251.0 Unallocated expenses — (24.3 ) — — Total $ 951.5 $ 137.2 $ 106.5 $ 19,720.6

Summary of Significant Accoun32

Summary of Significant Accounting Policies and Basis of Presentation Summary of Significant Accounting Policies and Basis of Presentation (Details) $ in Millions	3 Months Ended
	Sep. 26, 2015USD ($)
Summary of Significant Accounting Policies [Line Items]
Balance of non recourse receivables sold	$ 159.3
non recourse receivable activity	$ 12.3
Minimum [Member]
Summary of Significant Accounting Policies [Line Items]
Financial asset servicing fees paid	0.14%
Maximum [Member]
Summary of Significant Accounting Policies [Line Items]
Financial asset servicing fees paid	0.15%

Business Acquisitions (Details)

Business Acquisitions (Details) $ / shares in Units, € in Millions

Sep. 15, 2015USD ($)

Sep. 15, 2015EUR (€)

Aug. 28, 2015USD ($)

May. 12, 2015USD ($)

Mar. 30, 2015USD ($)$ / sharesshares

Mar. 30, 2015EUR (€)shares

Oct. 31, 2014USD ($)products

Sep. 26, 2015USD ($)

Sep. 27, 2014USD ($)

Jun. 27, 2015USD ($)shares

Nov. 08, 2013USD ($)

Business Acquisition [Line Items]

Goodwill

$ 4,987,100,000

$ 4,971,900,000

Interest Income (Expense), Net

43,400,000

$ 25,900,000

Senior Notes

4,722,700,000

4,720,900,000

$ 2,300,000,000

Proceeds from Issuance or Sale of Equity

999,300,000

Goodwill, Purchase Accounting Adjustments

(87,200,000)

Naturwohl Pharma [Member]

Business Acquisition [Line Items]

Total purchase consideration

[1]

$ 150,400,000

Cash and cash equivalents

[1]

4,600,000

Accounts Receivable

[1]

3,300,000

Inventories

[1]

1,700,000

Prepaid Expense and Other Current Assets

[1]

0

Goodwill

[1]

63,500,000

Other intangible assets

[1]

107,300,000

Total Assets

[1]

180,400,000

Accounts Payable

[1]

2,800,000

Accrued liabilities

[1]

900,000

Current net deferred income tax liabilities

[1]

900,000

Noncurrent net deferred income tax liabilities

[1]

25,400,000

Total liabilities

[1]

30,000,000

Net assets acquired

[1]

$ 150,400,000

Business Acquisition, Effective Date of Acquisition

Sep. 15, 2015

Sep. 15, 2015

Business Acquisition, Percentage of Voting Interests Acquired

100.00%

Scar Away

Business Acquisition [Line Items]

Total purchase consideration

[1]

$ 27,000,000

Cash and cash equivalents

[1]

0

Accounts Receivable

[1]

900,000

Inventories

[1]

0

Prepaid Expense and Other Current Assets

[1]

100,000

Goodwill

[1]

4,900,000

Other intangible assets

[1]

21,100,000

Total Assets

[1]

27,000,000

Accounts Payable

[1]

0

Accrued liabilities

[1]

0

Current net deferred income tax liabilities

[1]

0

Noncurrent net deferred income tax liabilities

[1]

0

Total liabilities

[1]

0

Net assets acquired

[1]

$ 27,000,000

Business Acquisition, Effective Date of Acquisition

Aug. 28, 2015

GSK

Business Acquisition [Line Items]

Total purchase consideration

[1]

$ 223,600,000

Cash and cash equivalents

[1]

0

Accounts Receivable

[1]

0

Inventories

[1]

0

Prepaid Expense and Other Current Assets

[1]

0

Goodwill

[1]

48,700,000

Other intangible assets

[1]

174,900,000

Total Assets

[1]

223,600,000

Accounts Payable

[1]

0

Accrued liabilities

[1]

0

Current net deferred income tax liabilities

[1]

0

Noncurrent net deferred income tax liabilities

[1]

0

Total liabilities

[1]

0

Net assets acquired

[1]

$ 223,600,000

Business Acquisition, Effective Date of Acquisition

Aug. 28, 2015

Other [Member]

Business Acquisition [Line Items]

Total purchase consideration

8,700,000

Business acquisitions, number of products purchased

2

Gelcaps

Business Acquisition [Line Items]

Total purchase consideration

$ 36,400,000

Cash and cash equivalents

4,600,000

Accounts Receivable

8,500,000

Inventories

7,200,000

Current net deferred tax assets

600,000

Prepaid Expense and Other Current Assets

2,300,000

Property, Plant, and Equipment

6,000,000

Goodwill

4,600,000

Other intangible assets

11,000,000

Noncurrent Assets

400,000

Total Assets

45,200,000

Accounts Payable

3,400,000

Accrued liabilities

1,600,000

Accrued payroll

0

Short term debt

0

Noncurrent net deferred income tax liabilities

3,700,000

Long-term debt

0

Noncurrent Liabilities

100,000

Total liabilities

8,800,000

Net assets acquired

36,400,000

Accrued customer programs

$ 0

Business Acquisition, Effective Date of Acquisition

May 12, 2015

Business Acquisition, Percentage of Voting Interests Acquired

100.00%

Omega

Business Acquisition [Line Items]

Total purchase consideration

$ 2,983,200,000

Cash and cash equivalents

14,700,000

Accounts Receivable

264,700,000

Inventories

207,100,000

Current net deferred tax assets

7,600,000

Prepaid Expense and Other Current Assets

39,200,000

Property, Plant, and Equipment

130,800,000

Goodwill

1,426,100,000

Other intangible assets

3,919,100,000

Noncurrent Assets

2,400,000

Total Assets

6,011,700,000

Accounts Payable

243,100,000

Accrued liabilities

44,500,000

Accrued payroll

51,300,000

Short term debt

24,600,000

Noncurrent net deferred income tax liabilities

1,071,700,000

Long-term debt

1,471,000,000

Noncurrent Liabilities

82,500,000

Total liabilities

3,028,500,000

Net assets acquired

2,983,200,000

Business Combination, Acquisition Related Costs

387,000,000

Accrued customer programs

$ 39,800,000

Shares, Issued | shares

5,400,000

Business Acquisition, Effective Date of Acquisition

Mar. 30, 2015

Mar. 30, 2015

Shares, Outstanding | shares

685,348,257

Business Acquisition, Percentage of Voting Interests Acquired

95.77%

Treasury Stock, Shares, Acquired | shares

30,243,983

30,243,983

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory

(7,400,000)

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment

9,600,000

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, net deferred taxes

31,600,000

Business Acquisition, Share Price | $ / shares

$ 167.64

Business Acquisition, Equity Interest Issued or Issuable, Value Assigned

$ 904,900,000

Business Acquisition, Cash Exchange

2,078,300,000

Goodwill, Purchase Accounting Adjustments

(87,000,000)

Lumara [Member]

Business Acquisition [Line Items]

Total purchase consideration

$ 83,000,000

Cash and cash equivalents

0

Accounts Receivable

2,900,000

Inventories

1,500,000

Current net deferred tax assets

0

Prepaid Expense and Other Current Assets

400,000

Property, Plant, and Equipment

100,000

Goodwill

0

Other intangible assets

82,000,000

Noncurrent Assets

0

Total Assets

86,900,000

Accounts Payable

0

Accrued liabilities

3,900,000

Accrued payroll

0

Short term debt

0

Noncurrent net deferred income tax liabilities

0

Long-term debt

0

Noncurrent Liabilities

0

Total liabilities

3,900,000

Net assets acquired

83,000,000

Accrued customer programs

$ 0

Business Acquisition, Effective Date of Acquisition

Oct. 31, 2014

Number of formulations | products

3

Maximum [Member] | Omega

Business Acquisition [Line Items]

Indemnification available from acquired company's sellers | €

€ 277

Administration [Member] | Omega

Business Acquisition [Line Items]

Business Combination, Acquisition Related Costs

29,700,000

Interest Net [Member] | Omega

Business Acquisition [Line Items]

Interest Income (Expense), Net

23,700,000

Other Expense [Member] | Omega

Business Acquisition [Line Items]

Business Combination, Acquisition Related Costs

324,000,000

Loss on extinguishment of debt [Member] | Omega

Business Acquisition [Line Items]

Gains (Losses) on Extinguishment of Debt

9,600,000

Inventories [Member] | Gelcaps

Business Acquisition [Line Items]

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory

$ 600,000

Inventories [Member] | Omega

Business Acquisition [Line Items]

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory

15,100,000

Property, Plant and Equipment [Member] | Gelcaps

Business Acquisition [Line Items]

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment

$ 900,000

Property, Plant and Equipment [Member] | Omega

Business Acquisition [Line Items]

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment

41,500,000

Long-term Debt [Member] | Omega

Business Acquisition [Line Items]

Business combination fair value adjustment

101,900,000

Indefinite-lived Intangible Assets [Member] | Omega

Business Acquisition [Line Items]

Indefinite-lived Intangible Assets, Purchase Accounting Adjustments

98,000,000

Indefinite-lived Intangible Assets [Member] | Omega

Business Acquisition [Line Items]

Indefinite-lived Intangible Assets, Purchase Accounting Adjustments

18,400,000

2014 bonds [Member]

Business Acquisition [Line Items]

Senior Notes

$ 1,600,000,000

Common Stock [Member]

Business Acquisition [Line Items]

Stock Issued During Period, Shares, New Issues | shares

6,800,000

Euro Member Countries, Euro | Naturwohl Pharma [Member]

Business Acquisition [Line Items]

Total purchase consideration | €

€ 133.5

Euro Member Countries, Euro | GSK

Business Acquisition [Line Items]

Total purchase consideration

$ 200,000,000

Euro Member Countries, Euro | Other [Member]

Business Acquisition [Line Items]

Total purchase consideration

$ 7,900,000

Euro Member Countries, Euro | Maximum [Member] | Omega

Business Acquisition [Line Items]

Indemnification available from acquired company's sellers

248,000,000

Trademarks [Member] | Naturwohl Pharma [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

15 years

15 years

Trademarks [Member] | Scar Away

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

25 years

Trademarks [Member] | GSK

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

25 years

Trademarks [Member] | Gelcaps

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

25 years

Customer Relationships [Member] | Naturwohl Pharma [Member]

Business Acquisition [Line Items]

Other intangible assets

[1]

$ 33,800,000

Finite-Lived Intangible Asset, Useful Life

15 years

15 years

Customer Relationships [Member] | Scar Away

Business Acquisition [Line Items]

Other intangible assets

[1]

$ 9,000,000

Finite-Lived Intangible Asset, Useful Life

15 years

Customer Relationships [Member] | GSK

Business Acquisition [Line Items]

Other intangible assets

[1]

$ 42,500,000

Finite-Lived Intangible Asset, Useful Life

15 years

Customer Relationships [Member] | Gelcaps

Business Acquisition [Line Items]

Other intangible assets

$ 6,600,000

Finite-Lived Intangible Asset, Useful Life

20 years

Customer Relationships [Member] | Omega

Business Acquisition [Line Items]

Other intangible assets

$ 1,393,900,000

Finite-Lived Intangible Asset, Useful Life

21 years

21 years

Customer Relationships [Member] | Lumara [Member]

Business Acquisition [Line Items]

Other intangible assets

$ 0

Noncompete Agreements [Member] | Naturwohl Pharma [Member]

Business Acquisition [Line Items]

Other intangible assets

[1]

$ 300,000

Finite-Lived Intangible Asset, Useful Life

3 years

3 years

Noncompete Agreements [Member] | Scar Away

Business Acquisition [Line Items]

Other intangible assets

[1]

$ 500,000

Finite-Lived Intangible Asset, Useful Life

4 years

Noncompete Agreements [Member] | GSK

Business Acquisition [Line Items]

Other intangible assets

[1]

$ 0

Noncompete Agreements [Member] | Omega

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

3 years

3 years

Licensing Agreements [Member] | Naturwohl Pharma [Member]

Business Acquisition [Line Items]

Other intangible assets

[1]

$ 21,400,000

Finite-Lived Intangible Asset, Useful Life

3 years

3 years

Licensing Agreements [Member] | Scar Away

Business Acquisition [Line Items]

Other intangible assets

[1]

0

Licensing Agreements [Member] | GSK

Business Acquisition [Line Items]

Other intangible assets

[1]

0

Non-solicit agreement [Member] | Omega

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

2 years

2 years

Trademarks and Trade Names [Member] | Naturwohl Pharma [Member]

Business Acquisition [Line Items]

Other intangible assets

[1]

$ 51,800,000

Trademarks and Trade Names [Member] | Scar Away

Business Acquisition [Line Items]

Other intangible assets

[1]

11,600,000

Trademarks and Trade Names [Member] | GSK

Business Acquisition [Line Items]

Other intangible assets

[1]

$ 132,400,000

Trademarks and Trade Names [Member] | Gelcaps

Business Acquisition [Line Items]

Other intangible assets

$ 4,400,000

Trademarks and Trade Names [Member] | Omega

Business Acquisition [Line Items]

Other intangible assets

$ 2,492,600,000

Finite-Lived Intangible Asset, Useful Life

8 years

8 years

Trademarks and Trade Names [Member] | Lumara [Member]

Business Acquisition [Line Items]

Other intangible assets

0

Brands [Member] | Omega

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

19 years

19 years

Developed Technology Rights [Member] | Gelcaps

Business Acquisition [Line Items]

Other intangible assets

0

Developed Technology Rights [Member] | Omega

Business Acquisition [Line Items]

Other intangible assets

$ 32,600,000

Developed Technology Rights [Member] | Lumara [Member]

Business Acquisition [Line Items]

Other intangible assets

0

Developed Technology Rights [Member] | Minimum [Member] | Omega

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

4 years

4 years

Developed Technology Rights [Member] | Maximum [Member] | Omega

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

13 years

13 years

Product Formulations [Member] | Gelcaps

Business Acquisition [Line Items]

Other intangible assets

$ 0

Product Formulations [Member] | Omega

Business Acquisition [Line Items]

Other intangible assets

$ 0

Product Formulations [Member] | Lumara [Member]

Business Acquisition [Line Items]

Other intangible assets

$ 82,000,000

Product Formulations [Member] | Minimum [Member] | Lumara [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

8 years

Product Formulations [Member] | Maximum [Member] | Lumara [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

12 years

[1]

Opening balance sheets are preliminary.

Goodwill and Other Intangible34

Goodwill and Other Intangible Assets - Goodwill (Details) $ in Millions	3 Months Ended
	Sep. 26, 2015USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 4,971.9
Business Acquisitions	117.1
Purchase Accounting Adjustments	(87.2)
Currency translation adjustment	(14.7)
Ending balance	4,987.1
CHC [Member]
Goodwill [Roll Forward]
Beginning balance	1,897.5
Business Acquisitions	4.9
Purchase Accounting Adjustments	(0.2)
Currency translation adjustment	(3.8)
Ending balance	1,898.4
BCH [Member]
Goodwill [Roll Forward]
Beginning balance	1,551.9
Business Acquisitions	112.2
Purchase Accounting Adjustments	(87)
Currency translation adjustment	0.4
Ending balance	1,577.5
Rx [Member]
Goodwill [Roll Forward]
Beginning balance	1,233.6
Business Acquisitions	0
Purchase Accounting Adjustments	0
Currency translation adjustment	(8.1)
Ending balance	1,225.5
Specialty Sciences [Member]
Goodwill [Roll Forward]
Beginning balance	200.7
Business Acquisitions	0
Purchase Accounting Adjustments	0
Currency translation adjustment	0
Ending balance	200.7
Other [Member]
Goodwill [Roll Forward]
Beginning balance	88.2
Business Acquisitions	0
Purchase Accounting Adjustments	0
Currency translation adjustment	(3.2)
Ending balance	$ 85

Goodwill and Other Intangible35

Goodwill and Other Intangible Assets - Intangible categories (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 26, 2015	Sep. 27, 2014	Jun. 27, 2015
Finite And Indefinite Lived Assets By Major Class [Line Items]
Intangible assets subject to amortization, Gross	$ 9,485.8		$ 9,160.6
Intangible assets subject to amortization, Accumulated Amortization	1,195.6		1,055
Intangible assets not subject to amortization	2,368.1		2,263.1
Total other intangible assets	11,853.9		11,423.7
Intangible assets amortization expense	147.6	$ 106.5
Trademarks, trade names and brands
Finite And Indefinite Lived Assets By Major Class [Line Items]
Intangible assets not subject to amortization	2,362.5		2,257.3
In Process Research and Development [Member]
Finite And Indefinite Lived Assets By Major Class [Line Items]
Intangible assets not subject to amortization	5.6		5.8
Distribution And License Agreements [Member]
Finite And Indefinite Lived Assets By Major Class [Line Items]
Intangible assets subject to amortization, Gross	6,064.2		6,029.9
Intangible assets subject to amortization, Accumulated Amortization	582.6		502.3
Developed Product Technology/Formulation and Product Rights [Member]
Finite And Indefinite Lived Assets By Major Class [Line Items]
Intangible assets subject to amortization, Gross	1,015.4		1,025.3
Intangible assets subject to amortization, Accumulated Amortization	402.5		383.1
Customer Relationships [Member]
Finite And Indefinite Lived Assets By Major Class [Line Items]
Intangible assets subject to amortization, Gross	1,888.2		1,749.9
Intangible assets subject to amortization, Accumulated Amortization	181.5		146.2
Trademarks, trade names and brands
Finite And Indefinite Lived Assets By Major Class [Line Items]
Intangible assets subject to amortization, Gross	502.8		340.8
Intangible assets subject to amortization, Accumulated Amortization	16.7		11.5
Noncompete Agreements [Member]
Finite And Indefinite Lived Assets By Major Class [Line Items]
Intangible assets subject to amortization, Gross	15.2		14.7
Intangible assets subject to amortization, Accumulated Amortization	$ 12.3		$ 11.9

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Sep. 26, 2015	Jun. 27, 2015
Inventory Disclosure [Abstract]
Finished goods	$ 504.7	$ 468.9
Work in process	163.2	158.2
Raw materials	220.1	211.8
Total Inventories	$ 888	$ 838.9

Fair value measurements - asset

Fair value measurements - assets and liabilities on a recurring basis (Details) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 26, 2015	Jun. 27, 2015	Nov. 08, 2013
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair Value, Assets, Level 1, Level 2, Level 3 Transfers, Amount	$ 0	$ 0
Senior Notes	4,722,700,000	4,720,900,000	$ 2,300,000,000
Long-term Debt	822,700,000	820,900,000
Debt Instrument, Fair Value Disclosure	890,900,000	902,400,000
Assets:
Investment securities	16,500,000	12,700,000
Foreign currency forward contracts	4,800,000	12,400,000
Funds associated with Israeli post employment benefits	16,500,000	17,300,000
Total assets	37,800,000	42,400,000
Liabilities:
Foreign currency forward contracts	5,900,000	4,600,000
Total liabilities	5,900,000	4,600,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Senior Notes	3,900,000,000	3,900,000,000
Debt Instrument, Fair Value Disclosure	3,811,500,000	3,850,700,000
Assets:
Investment securities	16,500,000	12,700,000
Foreign currency forward contracts	0	0
Funds associated with Israeli post employment benefits	0	0
Total assets	16,500,000	12,700,000
Liabilities:
Foreign currency forward contracts	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Assets:
Investment securities	0	0
Foreign currency forward contracts	4,800,000	12,400,000
Funds associated with Israeli post employment benefits	16,500,000	17,300,000
Total assets	21,300,000	29,700,000
Liabilities:
Foreign currency forward contracts	5,900,000	4,600,000
Total liabilities	5,900,000	4,600,000
Fair Value, Inputs, Level 3 [Member]
Assets:
Investment securities	0	0
Foreign currency forward contracts	0	0
Funds associated with Israeli post employment benefits	0	0
Total assets	0	0
Liabilities:
Foreign currency forward contracts	0	0
Total liabilities	$ 0	$ 0

Fair Value Measurements Fair va

Fair Value Measurements Fair value measurements - items not carried at fair value (Details) - USD ($) $ in Millions	Sep. 26, 2015	Jun. 27, 2015	Nov. 08, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Senior Notes	$ 4,722.7	$ 4,720.9	$ 2,300
Debt Instrument, Fair Value Disclosure	890.9	902.4
Fair Value, Inputs, Level 1 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Senior Notes	3,900	3,900
Debt Instrument, Fair Value Disclosure	$ 3,811.5	$ 3,850.7

Investments (Details)

Investments (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 26, 2015	Sep. 27, 2014	Jun. 27, 2015
Schedule of Equity Method Investments [Line Items]
Unrealized loss on equity method investments	$ (4.1)
Loss from Equity Method Investments		$ (3.1)
Unrealized Gain (Loss) on Investments [Abstract]
Equity securities, at cost less impairments	17.1		$ 17.1
Gross unrealized gains	10.6		5.7
Gross unrealized losses	(11.2)		(10.1)
Estimated fair value of equity securities	16.5		12.7
Other Noncurrent Assets [Member]
Schedule of Equity Method Investments [Line Items]
Cost Method Investments	6.9		6.8
Equity Method Investments	$ 48.5		$ 48.9

Derivative Instruments and He40

Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities - text links (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 26, 2015	Sep. 27, 2014	Jun. 27, 2015
Derivative [Line Items]
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	$ 1.8
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	(0.5)	$ (2.5)
Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net	(8.8)	(3.3)
Interest Rate Swap [Member] | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	$ 0	2.7
Foreign Exchange Forward [Member]
Derivative [Line Items]
Maximum Remaining Maturity of Foreign Currency Derivatives	15 months
Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	$ (0.5)	$ (5.2)
Foreign Exchange Contract [Member]
Derivative [Line Items]
Derivative, Notional Amount	$ 562.3		$ 452.3

Derivative Instruments and He41

Derivative Instruments and Hedging Activities - balance sheet location (Details) - USD ($) $ in Millions	Sep. 26, 2015	Jun. 27, 2015
Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Net	$ 2.3	$ 3.3
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	2.5	2
Designated as Hedging Instrument [Member] | Other Current Assets [Member] | Foreign Exchange Forward [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Net	2.3	3.3
Designated as Hedging Instrument [Member] | Accrued Liabilities [Member] | Foreign Exchange Forward [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	2.5	2
Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	3.4	2.6
Not Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Net	2.5	9.1
Not Designated as Hedging Instrument [Member] | Other Current Assets [Member] | Foreign Exchange Forward [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Net	2.5	9.1
Not Designated as Hedging Instrument [Member] | Accrued Liabilities [Member] | Foreign Exchange Forward [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	$ 3.4	$ 2.6

Derivative Instruments and He42

Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities - other comprehensive income movement (Details) - Designated as Hedging Instrument [Member] - USD ($) $ in Millions	3 Months Ended
	Sep. 26, 2015	Sep. 27, 2014
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	$ (0.5)	$ (2.5)
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	(0.4)	(0.7)
Interest Rate Swap [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	0	2.7
Foreign Exchange Forward [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	(0.5)	(5.2)
Interest Expense [Member] | Interest Rate Swap [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	(0.4)	(0.9)
Net sales [Member] | Foreign Exchange Forward [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	(0.1)	0.6
Other Nonoperating Income (Expense) [Member] | Foreign Exchange Forward [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	(0.1)	(0.8)
Cost of Sales [Member] | Foreign Exchange Forward [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	$ 0.2	$ 0.4

Derivative Instruments and He43

Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities- Non-designated derivatives (Details) - Not Designated as Hedging Instrument [Member] - USD ($) $ in Millions	3 Months Ended
	Sep. 26, 2015	Sep. 27, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	$ (8.8)	$ (3.3)
Foreign Exchange Forward [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	(8.9)	(1.8)
Foreign Exchange Forward [Member] | Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	$ 0.1	$ (1.5)

Indebtedness (Debt arrangements

Indebtedness (Debt arrangements) (details) € in Millions, $ in Millions

Apr. 08, 2015USD ($)

Apr. 08, 2015EUR (€)

Mar. 30, 2015USD ($)

Mar. 30, 2015EUR (€)

Dec. 05, 2014USD ($)

Dec. 02, 2014USD ($)

Sep. 26, 2015USD ($)

Sep. 27, 2014

Jun. 27, 2015USD ($)

Mar. 30, 2015EUR (€)

Dec. 05, 2014EUR (€)

Nov. 08, 2013USD ($)

Debt Instrument [Line Items]

Debt Instrument, Issuance Date

Dec. 5, 2014

Short-term debt

$ 86.9

$ 6.4

Senior Notes

$ 4,722.7

4,720.9

$ 2,300

Obligated repurchase par amount of public senior notes

101.00%

Other Long-term Debt

$ 6.3

6.6

Debt Instrument, Unamortized Discount (Premium), Net

(80.4)

(87.5)

Deferred financing fee

39

40.5

Debt, Long-term and Short-term, Combined Amount

5,375

5,311.4

Debt, Short Term and Current Portion of Long Term

145.1

64.6

Long-term debt, less current portion

5,229.9

5,246.9

Line of Credit Facility, Maximum Borrowing Capacity | €

€ 1,000

Line of Credit Facility, Fair Value of Amount Outstanding

$ 0

Term Loans [Member]

Debt Instrument [Line Items]

Change in control, Ownership percentage

35.00%

Public [Member]

Debt Instrument [Line Items]

Senior Notes

3,900

2014 Euro-Denominated Term Loan due December 5, 2019 [Member]

Debt Instrument [Line Items]

Term loans

$ 517.7

[1]

530.5

Debt Instrument, Maturity Date

Dec. 5, 2019

Dec. 5, 2019

1.30% Unsecured Senior Notes due November 8, 2016 [Member]

Debt Instrument [Line Items]

Senior Notes

$ 500

[2]

500

Debt Instrument, Face Amount

500

4.500% Unsecured Senior Notes due May 23, 2017 [Domain]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

4.50%

Senior Notes

$ 201.5

[1],[3]

201

Debt Instrument, Maturity Date

May 23, 2017

5.125% Unsecured Senior Notes due December 12, 2017 [Domain]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.125%

Senior Notes

$ 335.8

[1],[3]

335

Debt Instrument, Maturity Date

Dec. 12, 2017

2.30% Unsecured Senior notes November 8, 2018 [Member]

Debt Instrument [Line Items]

Senior Notes

$ 600

[2]

600

Debt Instrument, Face Amount

600

5.000% Unsecured Senior notes due May 23, 2019 [Domain]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Senior Notes

$ 134.3

[1],[3]

134.1

Debt Instrument, Maturity Date

May 23, 2019

3.5% Senior note due 2021 [Member]

Debt Instrument [Line Items]

Senior Notes

$ 500

[4]

500

5.105% Senior note due July 19, 2023 [Domain]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.105%

Senior Notes

$ 151.1

[1],[3]

150.8

Debt Instrument, Maturity Date

Jul. 19, 2023

4.00% Unsecured Senior Notes due November 15, 2023 [Member]

Debt Instrument [Line Items]

Senior Notes

$ 800

[2]

800

Debt Instrument, Face Amount

800

3.9% senior note due 2024 [Member]

Debt Instrument [Line Items]

Senior Notes

700

[4]

700

5.30% Unsecured Senior Notes due November 15, 2043 [Member]

Debt Instrument [Line Items]

Senior Notes

400

[2]

400

Debt Instrument, Face Amount

$ 400

4.9% Senior Loan due 2044 [Member]

Debt Instrument [Line Items]

Senior Notes

$ 400

[4]

$ 400

Revolving Credit Facility [Member]

Debt Instrument [Line Items]

Change in control, Ownership percentage

3500000000.00%

5.30% Unsecured Senior Notes due November 15, 2043 [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.30%

5.30%

Debt Instrument, Maturity Date

Nov. 15, 2043

Nov. 15, 2043

4.00% Unsecured Senior Notes due November 15, 2023 [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

4.00%

4.00%

Debt Instrument, Maturity Date

Nov. 15, 2023

Nov. 15, 2023

2.30% Unsecured Senior notes November 8, 2018 [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

2.30%

2.30%

Debt Instrument, Maturity Date

Nov. 8, 2018

Nov. 8, 2018

1.30% Unsecured Senior Notes due November 8, 2016 [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

1.30%

1.30%

Debt Instrument, Maturity Date

Nov. 8, 2016

Nov. 8, 2016

4.9% Senior Loan due 2044 [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

4.90%

4.90%

Debt Instrument, Face Amount

$ 400

Debt Instrument, Maturity Date

Dec. 15, 2044

3.9% senior note due 2024 [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

3.90%

3.90%

Debt Instrument, Face Amount

$ 700

Debt Instrument, Maturity Date

Dec. 15, 2024

2014 term loan die December 18, 2015 [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 300

3.5% Senior note due 2021 [Member]

Debt Instrument [Line Items]

Debt Instrument, Issuance Date

Dec. 2, 2014

Debt Instrument, Interest Rate, Stated Percentage

3.50%

3.50%

Debt Instrument, Face Amount

$ 500

Debt Instrument, Maturity Date

Dec. 15, 2021

2014 bonds [Member]

Debt Instrument [Line Items]

Senior Notes

$ 1,600

2014 Euro-Denominated Term Loan due December 5, 2019 [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount | €

614.3

2014 Euro-Denominated Term Loan due December 5, 2019 additional draw [Domain]

Debt Instrument [Line Items]

Debt Instrument, Face Amount | €

368.6

Revolving Credit Facility [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 600

Euro Member Countries, Euro | 2014 Euro-Denominated Term Loan due December 5, 2019 [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount | €

500

Euro Member Countries, Euro | 2014 Euro-Denominated Term Loan due December 5, 2019 additional draw [Domain]

Debt Instrument [Line Items]

Debt Instrument, Face Amount | €

€ 300

Omega

Debt Instrument [Line Items]

Amount debt exceeded par value

$ 101.9

Omega | Euro Member Countries, Euro

Debt Instrument [Line Items]

Amount debt exceeded par value | €

€ 93.6

Perrigo Co PLC [Member]

Debt Instrument [Line Items]

Long-term debt, less current portion

$ 5,229.9

$ 5,246.8

Omega

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt

$ 1,471

Debt Instrument, Maturity Date

Jan. 1, 2016

Jan. 1, 2016

Extinguishment of Debt, Amount

$ 539.1

Omega | 5.125% Retail Bond [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.125%

5.125%

Debt Instrument, Maturity Date

Jan. 1, 2017

Jan. 1, 2017

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt

$ 326.7

Omega | Credit facility indebtedness [Member]

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt

544.5

Omega | Over Draft [Member]

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt

$ 56

Omega | 6.19% Senior Note [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

6.19%

6.19%

Omega | 5.1045% Senior Note [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.1045%

5.1045%

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt

$ 147

Debt Instrument, Maturity Date

Jan. 1, 2023

Jan. 1, 2023

Omega | 4.5% Retail Bond [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

4.50%

4.50%

Debt Instrument, Maturity Date

Jan. 1, 2017

Jan. 1, 2017

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt

$ 196

Omega | 5.0% Retail Bond [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.00%

5.00%

Debt Instrument, Maturity Date

Jan. 1, 2019

Jan. 1, 2019

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt

$ 130.7

Omega | Euro Member Countries, Euro

Debt Instrument [Line Items]

Extinguishment of Debt, Amount | €

€ 500

Omega | Euro Member Countries, Euro | 5.125% Retail Bond [Member]

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt | €

€ 300

Omega | Euro Member Countries, Euro | Credit facility indebtedness [Member]

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt | €

500

Omega | Euro Member Countries, Euro | Over Draft [Member]

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt | €

51.4

Omega | Euro Member Countries, Euro | 5.1045% Senior Note [Member]

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | €

135

Omega | Euro Member Countries, Euro | 4.5% Retail Bond [Member]

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt | €

180

Omega | Euro Member Countries, Euro | 5.0% Retail Bond [Member]

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt | €

€ 120

Omega | Omega | 6.19% Senior Note [Member]

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt

$ 20

[1]

Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.

[2]

(3) Discussed below collectively as the "2013 Bonds."

[3]

(2) Debt assumed from Omega.

[4]

(1) Public bonds issued on December 2, 2014, discussed below collectively as the "2014 Bonds."

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) shares in Thousands, $ in Millions	Oct. 22, 2015	Sep. 26, 2015	Sep. 27, 2014
Numerator:
Net income		$ 112.6	$ 96.3
Denominator:
Basic		146,300	133,900
Dilutive effect of share-based awards		600	500
Weighted average shares outstanding for diluted EPS		146,900	134,400
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		100	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		154	186
Subsequent Event [Member]
Denominator:
Stock Repurchase Program, Authorized Amount	$ 500
Repurchase Agreements, Maturities	P3Y
Subsequent Event [Member] | Perrigo Co PLC [Member]
Denominator:
Stock Repurchase Program, Authorized Amount	$ 2,000

Accumulated Other Comprehensi46

Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 26, 2015	Sep. 27, 2014
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Balance at June 27, 2015	$ 102.4
OCI before reclassifications (net of tax)	(37.6)
Amounts reclassified from AOCI (net of tax)	0.4
Other comprehensive income (loss), net of tax	(37.2)	$ (65.3)
Balance as of September 26, 2015	65.2
Accumulated Translation Adjustment [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Balance at June 27, 2015	130.9
OCI before reclassifications (net of tax)	(39.8)
Amounts reclassified from AOCI (net of tax)	0
Other comprehensive income (loss), net of tax	(39.8)
Balance as of September 26, 2015	91.1
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Balance at June 27, 2015	(16.3)
OCI before reclassifications (net of tax)	(0.3)
Amounts reclassified from AOCI (net of tax)	0.4
Other comprehensive income (loss), net of tax	0.1
Balance as of September 26, 2015	(16.2)
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Balance at June 27, 2015	(3)
OCI before reclassifications (net of tax)	2.5
Amounts reclassified from AOCI (net of tax)	0
Other comprehensive income (loss), net of tax	2.5
Balance as of September 26, 2015	(0.5)
Accumulated Defined Benefit Plans Adjustment [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Balance at June 27, 2015	(9.2)
OCI before reclassifications (net of tax)	0
Amounts reclassified from AOCI (net of tax)	0
Other comprehensive income (loss), net of tax	0
Balance as of September 26, 2015	$ (9.2)

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Sep. 26, 2015	Sep. 27, 2014	Jun. 27, 2015
Income Taxes [Line Items]
Effective tax rate on income from continuing operations	14.80%	11.40%
Unrecognized Tax Benefits, Including Income Tax Penalties And Interest Accrued	$ 399		$ 384.3
Unrecognized tax benefits liability, interest and penalties accrued	$ 69		65.7
Income Tax Examination, Penalties and Interest Expense			8
Incremental tax obligation			$ 68.9

Commitments and Contingencies (

Commitments and Contingencies (Details) - Texas Medicaid [Member] - USD ($) $ in Millions	Sep. 26, 2015	Mar. 28, 2015
Loss Contingencies [Line Items]
Loss Contingency Accrual	$ 15	$ 9
Loss Contingency, Receivable		$ 7

Segment Information (Details)

Segment Information (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 26, 2015	Sep. 27, 2014	Jun. 27, 2015
Segment Reporting Information [Line Items]
Net sales	$ 1,344.7	$ 951.5
Operating Income (Loss)	188.6	137.2
Intangible assets amortization expense	147.6	106.5
Total Assets	19,703.1		$ 19,720.6
CHC [Member]
Segment Reporting Information [Line Items]
Net sales	675.2	640.3
Operating Income (Loss)	117.3	74.8
Intangible assets amortization expense	19.4	16.2
Total Assets	4,211.2		4,381.6
BCH [Member]
Segment Reporting Information [Line Items]
Net sales	302.2	0
Operating Income (Loss)	4.4	0
Intangible assets amortization expense	36.3	0
Total Assets	6,728		6,441.1
Rx [Member]
Segment Reporting Information [Line Items]
Net sales	260.3	194.5
Operating Income (Loss)	91	64.7
Intangible assets amortization expense	18.6	17
Total Assets	2,597.6		2,667.9
Specialty Sciences [Member]
Segment Reporting Information [Line Items]
Net sales	84.5	91.9
Operating Income (Loss)	9	14.9
Intangible assets amortization expense	72.8	72.8
Total Assets	5,920.8		5,979
Other Segments [Member]
Segment Reporting Information [Line Items]
Net sales	22.5	24.8
Operating Income (Loss)	6.2	7.1
Intangible assets amortization expense	0.5	0.5
Total Assets	245.5		251
Unallocated expenses
Segment Reporting Information [Line Items]
Net sales	0
Operating Income (Loss)	(39.3)	(24.3)
Intangible assets amortization expense	0	$ 0
Total Assets	$ 0		$ 0